CN115710215A - 用于治疗癌症的苯乙炔基取代苯和杂环及其应用 - Google Patents
用于治疗癌症的苯乙炔基取代苯和杂环及其应用 Download PDFInfo
- Publication number
- CN115710215A CN115710215A CN202211430818.8A CN202211430818A CN115710215A CN 115710215 A CN115710215 A CN 115710215A CN 202211430818 A CN202211430818 A CN 202211430818A CN 115710215 A CN115710215 A CN 115710215A
- Authority
- CN
- China
- Prior art keywords
- dmso
- nmr
- actual measurement
- cancer
- ethynyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000000623 heterocyclic group Chemical class 0.000 title claims abstract description 63
- -1 Phenylethynyl Chemical group 0.000 title claims abstract description 50
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 30
- 201000011510 cancer Diseases 0.000 title claims abstract description 27
- 150000001555 benzenes Chemical class 0.000 title abstract description 23
- 239000003814 drug Substances 0.000 claims abstract description 7
- 150000001875 compounds Chemical class 0.000 claims description 23
- 206010009944 Colon cancer Diseases 0.000 claims description 19
- 239000008194 pharmaceutical composition Substances 0.000 claims description 13
- 150000003839 salts Chemical class 0.000 claims description 13
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 9
- 206010060862 Prostate cancer Diseases 0.000 claims description 4
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 4
- 201000007270 liver cancer Diseases 0.000 claims description 4
- 208000014018 liver neoplasm Diseases 0.000 claims description 4
- 206010006187 Breast cancer Diseases 0.000 claims description 3
- 208000026310 Breast neoplasm Diseases 0.000 claims description 3
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 3
- 206010033128 Ovarian cancer Diseases 0.000 claims description 3
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 3
- 208000032839 leukemia Diseases 0.000 claims description 3
- 201000005202 lung cancer Diseases 0.000 claims description 3
- 208000020816 lung neoplasm Diseases 0.000 claims description 3
- 238000002360 preparation method Methods 0.000 claims description 3
- 230000002265 prevention Effects 0.000 claims description 3
- CVVRQIDVQBEHFQ-UHFFFAOYSA-N FC1=C(C(=CC=C1)F)C#CC=1C=C2C(=CC=NC2=CC=1)N(C)C Chemical group FC1=C(C(=CC=C1)F)C#CC=1C=C2C(=CC=NC2=CC=1)N(C)C CVVRQIDVQBEHFQ-UHFFFAOYSA-N 0.000 claims description 2
- UHOVQNZJYSORNB-UHFFFAOYSA-N monobenzene Natural products C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 abstract description 34
- 229910052757 nitrogen Inorganic materials 0.000 abstract description 7
- 230000002401 inhibitory effect Effects 0.000 abstract description 6
- 239000002246 antineoplastic agent Substances 0.000 abstract description 4
- 230000009702 cancer cell proliferation Effects 0.000 abstract description 4
- 238000004364 calculation method Methods 0.000 description 108
- 238000005259 measurement Methods 0.000 description 90
- 238000000132 electrospray ionisation Methods 0.000 description 55
- 238000004458 analytical method Methods 0.000 description 40
- 238000004440 column chromatography Methods 0.000 description 25
- 125000000217 alkyl group Chemical group 0.000 description 21
- 238000004587 chromatography analysis Methods 0.000 description 21
- 229910052736 halogen Inorganic materials 0.000 description 14
- 150000002367 halogens Chemical class 0.000 description 13
- 238000000034 method Methods 0.000 description 12
- 125000003545 alkoxy group Chemical group 0.000 description 11
- UZFMOKQJFYMBGY-UHFFFAOYSA-N 4-hydroxy-TEMPO Chemical compound CC1(C)CC(O)CC(C)(C)N1[O] UZFMOKQJFYMBGY-UHFFFAOYSA-N 0.000 description 10
- 208000029742 colonic neoplasm Diseases 0.000 description 10
- 230000000694 effects Effects 0.000 description 9
- 230000014509 gene expression Effects 0.000 description 9
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 8
- 101710135898 Myc proto-oncogene protein Proteins 0.000 description 7
- 102100038895 Myc proto-oncogene protein Human genes 0.000 description 7
- 101710150448 Transcriptional regulator Myc Proteins 0.000 description 7
- BIFLARAADMSAQE-UHFFFAOYSA-N 2-ethynyl-1,3-difluorobenzene Chemical group FC1=CC=CC(F)=C1C#C BIFLARAADMSAQE-UHFFFAOYSA-N 0.000 description 6
- QZZYWTILFJLXLF-UHFFFAOYSA-N C1=CC(N(C)C)=CC=C1C#CC1=C(F)C=CC=C1F Chemical compound C1=CC(N(C)C)=CC=C1C#CC1=C(F)C=CC=C1F QZZYWTILFJLXLF-UHFFFAOYSA-N 0.000 description 6
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 6
- 238000001516 cell proliferation assay Methods 0.000 description 6
- 239000000460 chlorine Substances 0.000 description 6
- AWJUIBRHMBBTKR-UHFFFAOYSA-N isoquinoline Chemical compound C1=NC=CC2=CC=CC=C21 AWJUIBRHMBBTKR-UHFFFAOYSA-N 0.000 description 6
- 238000013456 study Methods 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 125000001462 1-pyrrolyl group Chemical group [*]N1C([H])=C([H])C([H])=C1[H] 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 5
- PJANXHGTPQOBST-UHFFFAOYSA-N stilbene Chemical compound C=1C=CC=CC=1C=CC1=CC=CC=C1 PJANXHGTPQOBST-UHFFFAOYSA-N 0.000 description 5
- 235000021286 stilbenes Nutrition 0.000 description 5
- 101150118885 wif1 gene Proteins 0.000 description 5
- BAXOFTOLAUCFNW-UHFFFAOYSA-N 1H-indazole Chemical compound C1=CC=C2C=NNC2=C1 BAXOFTOLAUCFNW-UHFFFAOYSA-N 0.000 description 4
- PBSAPNMLMMODBN-UHFFFAOYSA-N FC1=C(C(=CC=C1)F)C#CC1=CN=C(C2=CC=CC=C12)N(C)C Chemical compound FC1=C(C(=CC=C1)F)C#CC1=CN=C(C2=CC=CC=C12)N(C)C PBSAPNMLMMODBN-UHFFFAOYSA-N 0.000 description 4
- 101001047090 Homo sapiens Potassium voltage-gated channel subfamily H member 2 Proteins 0.000 description 4
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 4
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 4
- 238000003477 Sonogashira cross-coupling reaction Methods 0.000 description 4
- PJANXHGTPQOBST-VAWYXSNFSA-N Stilbene Natural products C=1C=CC=CC=1/C=C/C1=CC=CC=C1 PJANXHGTPQOBST-VAWYXSNFSA-N 0.000 description 4
- JRXXLCKWQFKACW-UHFFFAOYSA-N biphenylacetylene Chemical class C1=CC=CC=C1C#CC1=CC=CC=C1 JRXXLCKWQFKACW-UHFFFAOYSA-N 0.000 description 4
- 229910052731 fluorine Inorganic materials 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 4
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 4
- 125000001449 isopropyl group Chemical class [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 4
- 230000035755 proliferation Effects 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical group [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- DNIUOHYRNWXVOD-UHFFFAOYSA-N FC1=C(C(=CC=C1)F)C#CC1=CN=C(C2=CC=CC=C12)NC Chemical compound FC1=C(C(=CC=C1)F)C#CC1=CN=C(C2=CC=CC=C12)NC DNIUOHYRNWXVOD-UHFFFAOYSA-N 0.000 description 3
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical group FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 3
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 3
- MEFKEPWMEQBLKI-AIRLBKTGSA-N S-adenosyl-L-methioninate Chemical compound O[C@@H]1[C@H](O)[C@@H](C[S+](CC[C@H](N)C([O-])=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 MEFKEPWMEQBLKI-AIRLBKTGSA-N 0.000 description 3
- 102100035947 S-adenosylmethionine synthase isoform type-2 Human genes 0.000 description 3
- 229960001570 ademetionine Drugs 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 230000010261 cell growth Effects 0.000 description 3
- 229910052801 chlorine Chemical group 0.000 description 3
- 229940125898 compound 5 Drugs 0.000 description 3
- 239000011737 fluorine Substances 0.000 description 3
- 125000005843 halogen group Chemical group 0.000 description 3
- 150000002391 heterocyclic compounds Chemical class 0.000 description 3
- 102000046896 human KCNH2 Human genes 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 238000007339 nucleophilic aromatic substitution reaction Methods 0.000 description 3
- 125000004076 pyridyl group Chemical group 0.000 description 3
- 238000001953 recrystallisation Methods 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 238000001262 western blot Methods 0.000 description 3
- FLBAYUMRQUHISI-UHFFFAOYSA-N 1,8-naphthyridine Chemical compound N1=CC=CC2=CC=CN=C21 FLBAYUMRQUHISI-UHFFFAOYSA-N 0.000 description 2
- PVOAHINGSUIXLS-UHFFFAOYSA-N 1-Methylpiperazine Chemical compound CN1CCNCC1 PVOAHINGSUIXLS-UHFFFAOYSA-N 0.000 description 2
- MVXVYAKCVDQRLW-UHFFFAOYSA-N 1h-pyrrolo[2,3-b]pyridine Chemical compound C1=CN=C2NC=CC2=C1 MVXVYAKCVDQRLW-UHFFFAOYSA-N 0.000 description 2
- WXTMDXOMEHJXQO-UHFFFAOYSA-N 2,5-dihydroxybenzoic acid Chemical compound OC(=O)C1=CC(O)=CC=C1O WXTMDXOMEHJXQO-UHFFFAOYSA-N 0.000 description 2
- QLWIXTNGAHLJBP-UHFFFAOYSA-N ClC1=CC=C2C(=CC=NC2=C1)C#CC1=C(C=CC=C1F)F Chemical compound ClC1=CC=C2C(=CC=NC2=C1)C#CC1=C(C=CC=C1F)F QLWIXTNGAHLJBP-UHFFFAOYSA-N 0.000 description 2
- DZFMXIHBPMXGES-UHFFFAOYSA-N ClC1=CC=NC2=CC(=CC=C12)C#CC1=C(C=CC=C1F)F Chemical compound ClC1=CC=NC2=CC(=CC=C12)C#CC1=C(C=CC=C1F)F DZFMXIHBPMXGES-UHFFFAOYSA-N 0.000 description 2
- CHKDJSDQQIGMGQ-UHFFFAOYSA-N ClC1=CC=NC2=CC=C(C=C12)C#CC1=C(C=CC=C1F)F Chemical compound ClC1=CC=NC2=CC=C(C=C12)C#CC1=C(C=CC=C1F)F CHKDJSDQQIGMGQ-UHFFFAOYSA-N 0.000 description 2
- FXRWYLGFFCXTHK-UHFFFAOYSA-N ClC1=NC2=CC=CC=C2C=C1C#CC1=C(C=CC=C1F)F Chemical compound ClC1=NC2=CC=CC=C2C=C1C#CC1=C(C=CC=C1F)F FXRWYLGFFCXTHK-UHFFFAOYSA-N 0.000 description 2
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 2
- BHSMZLZFHZFDLK-UHFFFAOYSA-N FC1=C(C(=CC=C1)F)C#CC1=C2C=CC=NC2=CC=C1 Chemical compound FC1=C(C(=CC=C1)F)C#CC1=C2C=CC=NC2=CC=C1 BHSMZLZFHZFDLK-UHFFFAOYSA-N 0.000 description 2
- NHOHKKUNMFBJEK-UHFFFAOYSA-N FC1=C(C(=CC=C1)F)C#CC1=C2C=CN=CC2=CC=C1 Chemical compound FC1=C(C(=CC=C1)F)C#CC1=C2C=CN=CC2=CC=C1 NHOHKKUNMFBJEK-UHFFFAOYSA-N 0.000 description 2
- YSDYJBSNLBCFIZ-UHFFFAOYSA-N FC1=C(C(=CC=C1)F)C#CC1=CC=C(C=C1)N1C(=CC=C1C)C Chemical compound FC1=C(C(=CC=C1)F)C#CC1=CC=C(C=C1)N1C(=CC=C1C)C YSDYJBSNLBCFIZ-UHFFFAOYSA-N 0.000 description 2
- KLTRQPXDZMENGD-UHFFFAOYSA-N FC1=C(C(=CC=C1)F)C#CC1=CC=C(C=C1)N1C(CCCC1)=O Chemical compound FC1=C(C(=CC=C1)F)C#CC1=CC=C(C=C1)N1C(CCCC1)=O KLTRQPXDZMENGD-UHFFFAOYSA-N 0.000 description 2
- DJTYQBVRONKHSO-UHFFFAOYSA-N FC1=C(C(=CC=C1)F)C#CC1=CC=C(C=C1)N1C=CC=C1 Chemical compound FC1=C(C(=CC=C1)F)C#CC1=CC=C(C=C1)N1C=CC=C1 DJTYQBVRONKHSO-UHFFFAOYSA-N 0.000 description 2
- OHENVUNDNBTBCQ-UHFFFAOYSA-N FC1=C(C(=CC=C1)F)C#CC1=CC=C(C=C1)N1CCN(CC1)C Chemical compound FC1=C(C(=CC=C1)F)C#CC1=CC=C(C=C1)N1CCN(CC1)C OHENVUNDNBTBCQ-UHFFFAOYSA-N 0.000 description 2
- ICHOOKDNMOFTSG-UHFFFAOYSA-N FC1=C(C(=CC=C1)F)C#CC1=CC=C(C=C1)N1CCOCC1 Chemical compound FC1=C(C(=CC=C1)F)C#CC1=CC=C(C=C1)N1CCOCC1 ICHOOKDNMOFTSG-UHFFFAOYSA-N 0.000 description 2
- ZSPZCDHCLBGLFC-UHFFFAOYSA-N FC1=C(C(=CC=C1)F)C#CC1=CC=C(C=N1)N(C)C Chemical compound FC1=C(C(=CC=C1)F)C#CC1=CC=C(C=N1)N(C)C ZSPZCDHCLBGLFC-UHFFFAOYSA-N 0.000 description 2
- CWUSFTYDLGGYKO-UHFFFAOYSA-N FC1=C(C(=CC=C1)F)C#CC1=CC=C2C(=CC=NC2=C1)N Chemical compound FC1=C(C(=CC=C1)F)C#CC1=CC=C2C(=CC=NC2=C1)N CWUSFTYDLGGYKO-UHFFFAOYSA-N 0.000 description 2
- GJXJWYLFLYIJJX-UHFFFAOYSA-N FC1=C(C(=CC=C1)F)C#CC1=CC=C2C=NC=NC2=C1 Chemical compound FC1=C(C(=CC=C1)F)C#CC1=CC=C2C=NC=NC2=C1 GJXJWYLFLYIJJX-UHFFFAOYSA-N 0.000 description 2
- WHKMTVYHWVHVKO-UHFFFAOYSA-N FC1=C(C(=CC=C1)F)C#CC1=CC=NC2=CC=CC=C12 Chemical compound FC1=C(C(=CC=C1)F)C#CC1=CC=NC2=CC=CC=C12 WHKMTVYHWVHVKO-UHFFFAOYSA-N 0.000 description 2
- KVDVSMGIXZBJTD-UHFFFAOYSA-N FC1=C(C(=CC=C1)F)C#CC1=CN=C(C2=CC=CC=C12)N Chemical compound FC1=C(C(=CC=C1)F)C#CC1=CN=C(C2=CC=CC=C12)N KVDVSMGIXZBJTD-UHFFFAOYSA-N 0.000 description 2
- QDPWNCOTFMIWSU-UHFFFAOYSA-N FC1=C(C(=CC=C1)F)C#CC1=CN=C(C=2C=CC=NC1=2)N(C)C Chemical compound FC1=C(C(=CC=C1)F)C#CC1=CN=C(C=2C=CC=NC1=2)N(C)C QDPWNCOTFMIWSU-UHFFFAOYSA-N 0.000 description 2
- HQWQTMFVGCMIPH-UHFFFAOYSA-N FC1=C(C(=CC=C1)F)C#CC=1C=C2C(=CC=NC2=CC=1)N Chemical compound FC1=C(C(=CC=C1)F)C#CC=1C=C2C(=CC=NC2=CC=1)N HQWQTMFVGCMIPH-UHFFFAOYSA-N 0.000 description 2
- DCMBSGDTHRMINO-UHFFFAOYSA-N FC1=C(C(=CC=C1)F)C#CC=1C=C2C=CC(=NC2=CC=1)N(C)C Chemical compound FC1=C(C(=CC=C1)F)C#CC=1C=C2C=CC(=NC2=CC=1)N(C)C DCMBSGDTHRMINO-UHFFFAOYSA-N 0.000 description 2
- IIUNPEPSNXZGFQ-UHFFFAOYSA-N FC1=C(C(=CC=C1)F)C#CC=1C=C2C=CC=NC2=CC=1 Chemical compound FC1=C(C(=CC=C1)F)C#CC=1C=C2C=CC=NC2=CC=1 IIUNPEPSNXZGFQ-UHFFFAOYSA-N 0.000 description 2
- SPPDIZMJRZTHGD-UHFFFAOYSA-N FC1=C(C(=CC=C1)F)C#CC=1C=C2C=CN(C2=CC=1)C Chemical compound FC1=C(C(=CC=C1)F)C#CC=1C=C2C=CN(C2=CC=1)C SPPDIZMJRZTHGD-UHFFFAOYSA-N 0.000 description 2
- RWAMUWJKCKHACQ-UHFFFAOYSA-N FC1=C(C(=CC=C1)F)C#CC=1C=C2C=CN=CC2=CC=1 Chemical compound FC1=C(C(=CC=C1)F)C#CC=1C=C2C=CN=CC2=CC=1 RWAMUWJKCKHACQ-UHFFFAOYSA-N 0.000 description 2
- WPGKTQBUUDFLKV-UHFFFAOYSA-N FC1=C(C(=CC=C1)F)C#CC=1C=C2C=CNC2=CC=1 Chemical compound FC1=C(C(=CC=C1)F)C#CC=1C=C2C=CNC2=CC=1 WPGKTQBUUDFLKV-UHFFFAOYSA-N 0.000 description 2
- NXDWRSCVPRJNKZ-UHFFFAOYSA-N FC1=C(C(=CC=C1)F)C#CC=1C=C2C=NNC2=CC=1 Chemical compound FC1=C(C(=CC=C1)F)C#CC=1C=C2C=NNC2=CC=1 NXDWRSCVPRJNKZ-UHFFFAOYSA-N 0.000 description 2
- QQILRSXFVWBYKM-UHFFFAOYSA-N FC1=C(C(=CC=C1)F)C#CC=1C=CC(=NC=1)N(C)C Chemical compound FC1=C(C(=CC=C1)F)C#CC=1C=CC(=NC=1)N(C)C QQILRSXFVWBYKM-UHFFFAOYSA-N 0.000 description 2
- ZDGMOTBKSLTLEF-UHFFFAOYSA-N FC1=C(C(=CC=C1)F)C#CC=1C=CC=C2C=CC=NC=12 Chemical compound FC1=C(C(=CC=C1)F)C#CC=1C=CC=C2C=CC=NC=12 ZDGMOTBKSLTLEF-UHFFFAOYSA-N 0.000 description 2
- HTRVWZUDUGERSS-UHFFFAOYSA-N FC1=C(C(=CC=C1)F)C#CC=1C=NC2=C(C=CC=C2C=1)F Chemical compound FC1=C(C(=CC=C1)F)C#CC=1C=NC2=C(C=CC=C2C=1)F HTRVWZUDUGERSS-UHFFFAOYSA-N 0.000 description 2
- DIQPBYPLJRJBGF-UHFFFAOYSA-N FC1=C(C(=CC=C1)F)C#CC=1C=NC2=CC(=CC=C2C=1)F Chemical compound FC1=C(C(=CC=C1)F)C#CC=1C=NC2=CC(=CC=C2C=1)F DIQPBYPLJRJBGF-UHFFFAOYSA-N 0.000 description 2
- AGUDUSRDMCKOJE-UHFFFAOYSA-N FC1=C(C(=CC=C1)F)C#CC=1C=NC2=CC=C(C=C2C=1)N Chemical compound FC1=C(C(=CC=C1)F)C#CC=1C=NC2=CC=C(C=C2C=1)N AGUDUSRDMCKOJE-UHFFFAOYSA-N 0.000 description 2
- WAZJQQDXWIIAMZ-UHFFFAOYSA-N FC1=C(C(=CC=C1)F)C#CC=1N=CC(=NC=1)N(C)C Chemical compound FC1=C(C(=CC=C1)F)C#CC=1N=CC(=NC=1)N(C)C WAZJQQDXWIIAMZ-UHFFFAOYSA-N 0.000 description 2
- GUKNHWMDAKTMNT-UHFFFAOYSA-N FC=1C=NC=C(C=1C#CC1=CC=C(N(C)C)C=C1)F Chemical compound FC=1C=NC=C(C=1C#CC1=CC=C(N(C)C)C=C1)F GUKNHWMDAKTMNT-UHFFFAOYSA-N 0.000 description 2
- JCGCPXFSSPCMMG-UHFFFAOYSA-N FC=1C=NC=C(C=1C#CC1=CC=C(N)C=C1)F Chemical compound FC=1C=NC=C(C=1C#CC1=CC=C(N)C=C1)F JCGCPXFSSPCMMG-UHFFFAOYSA-N 0.000 description 2
- MBCMWOTUYINQEW-UHFFFAOYSA-N FC=1C=NC=C(C=1C#CC1=CC=C(NC)C=C1)F Chemical compound FC=1C=NC=C(C=1C#CC1=CC=C(NC)C=C1)F MBCMWOTUYINQEW-UHFFFAOYSA-N 0.000 description 2
- OSLWRBZJZXXAFG-UHFFFAOYSA-N FC=1C=NC=C(C=1C#CC1=CC=CC=C1)F Chemical compound FC=1C=NC=C(C=1C#CC1=CC=CC=C1)F OSLWRBZJZXXAFG-UHFFFAOYSA-N 0.000 description 2
- 101000947881 Homo sapiens S-adenosylmethionine synthase isoform type-2 Proteins 0.000 description 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
- JLTDJTHDQAWBAV-UHFFFAOYSA-N N,N-dimethylaniline Chemical group CN(C)C1=CC=CC=C1 JLTDJTHDQAWBAV-UHFFFAOYSA-N 0.000 description 2
- KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- 102100026115 S-adenosylmethionine synthase isoform type-1 Human genes 0.000 description 2
- 102000013814 Wnt Human genes 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 125000003118 aryl group Chemical group 0.000 description 2
- 150000001503 aryl iodides Chemical class 0.000 description 2
- 230000003197 catalytic effect Effects 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 230000005754 cellular signaling Effects 0.000 description 2
- 125000001309 chloro group Chemical class Cl* 0.000 description 2
- 150000001991 dicarboxylic acids Chemical class 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 230000003463 hyperproliferative effect Effects 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 229930182817 methionine Natural products 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- XUWHAWMETYGRKB-UHFFFAOYSA-N piperidin-2-one Chemical compound O=C1CCCCN1 XUWHAWMETYGRKB-UHFFFAOYSA-N 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 238000004237 preparative chromatography Methods 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 150000003335 secondary amines Chemical class 0.000 description 2
- 150000001629 stilbenes Chemical class 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 230000035899 viability Effects 0.000 description 2
- VSOSXKMEQPYESP-UHFFFAOYSA-N 1,6-naphthyridine Chemical compound C1=CN=CC2=CC=CN=C21 VSOSXKMEQPYESP-UHFFFAOYSA-N 0.000 description 1
- PZMMTXHPJQTRSP-UHFFFAOYSA-N 1-chloro-4-iodoisoquinoline Chemical compound C1=CC=C2C(Cl)=NC=C(I)C2=C1 PZMMTXHPJQTRSP-UHFFFAOYSA-N 0.000 description 1
- JEXQHFHWSRCHPV-UHFFFAOYSA-N 4-iodoisoquinolin-1-amine Chemical compound C1=CC=C2C(N)=NC=C(I)C2=C1 JEXQHFHWSRCHPV-UHFFFAOYSA-N 0.000 description 1
- 125000006306 4-iodophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1I 0.000 description 1
- NSPMIYGKQJPBQR-UHFFFAOYSA-N 4H-1,2,4-triazole Chemical compound C=1N=CNN=1 NSPMIYGKQJPBQR-UHFFFAOYSA-N 0.000 description 1
- 230000035502 ADME Effects 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- QCZWMQMARYMWAS-UHFFFAOYSA-N CN(C)N1CN=CC=C1 Chemical group CN(C)N1CN=CC=C1 QCZWMQMARYMWAS-UHFFFAOYSA-N 0.000 description 1
- GNKGJCADVDDFAY-UHFFFAOYSA-N CN(N1CC2=CC=CC=C2C=C1)C Chemical class CN(N1CC2=CC=CC=C2C=C1)C GNKGJCADVDDFAY-UHFFFAOYSA-N 0.000 description 1
- 229940123587 Cell cycle inhibitor Drugs 0.000 description 1
- ZGBDXSZSDCKLQQ-UHFFFAOYSA-N ClC1=C(C=NC2=CC=CC=C12)C#CC1=C(C=CC=C1F)F Chemical compound ClC1=C(C=NC2=CC=CC=C12)C#CC1=C(C=CC=C1F)F ZGBDXSZSDCKLQQ-UHFFFAOYSA-N 0.000 description 1
- OKERFZJQFHDTEU-UHFFFAOYSA-N ClC1=NC2=CC=C(C=C2C=C1)C#CC1=C(C=CC=C1F)F Chemical compound ClC1=NC2=CC=C(C=C2C=C1)C#CC1=C(C=CC=C1F)F OKERFZJQFHDTEU-UHFFFAOYSA-N 0.000 description 1
- UOVQBSKTPBVSDW-UHFFFAOYSA-N ClC1=NC=C(C2=CC=CC=C12)C#CC1=C(C=CC=C1F)F Chemical compound ClC1=NC=C(C2=CC=CC=C12)C#CC1=C(C=CC=C1F)F UOVQBSKTPBVSDW-UHFFFAOYSA-N 0.000 description 1
- 102000016736 Cyclin Human genes 0.000 description 1
- 108050006400 Cyclin Proteins 0.000 description 1
- 102000006311 Cyclin D1 Human genes 0.000 description 1
- 108010058546 Cyclin D1 Proteins 0.000 description 1
- 102100033270 Cyclin-dependent kinase inhibitor 1 Human genes 0.000 description 1
- 101710157567 Cyclin-dependent kinase inhibitor 1 Proteins 0.000 description 1
- 238000007698 E/Z-isomerization reaction Methods 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- UPMSVQCTWCRCAT-UHFFFAOYSA-N FC1=C(C(=CC=C1)F)C#CC1=C2C=NNC2=CC=C1 Chemical compound FC1=C(C(=CC=C1)F)C#CC1=C2C=NNC2=CC=C1 UPMSVQCTWCRCAT-UHFFFAOYSA-N 0.000 description 1
- VKYFRDUJSLUUNC-UHFFFAOYSA-N FC1=C(C(=CC=C1)F)C#CC1=CC=C2C=CC=NC2=C1 Chemical compound FC1=C(C(=CC=C1)F)C#CC1=CC=C2C=CC=NC2=C1 VKYFRDUJSLUUNC-UHFFFAOYSA-N 0.000 description 1
- GWTJAHWHBQXHQS-UHFFFAOYSA-N FC1=C(C(=CC=C1)F)C#CC1=CC=C2C=NN(C2=C1)C Chemical compound FC1=C(C(=CC=C1)F)C#CC1=CC=C2C=NN(C2=C1)C GWTJAHWHBQXHQS-UHFFFAOYSA-N 0.000 description 1
- AJBKOYTVXDHUSH-UHFFFAOYSA-N FC1=C(C(=CC=C1)F)C#CC1=CN=C(C2=CC=CC=C12)N1CCN(CC1)C Chemical compound FC1=C(C(=CC=C1)F)C#CC1=CN=C(C2=CC=CC=C12)N1CCN(CC1)C AJBKOYTVXDHUSH-UHFFFAOYSA-N 0.000 description 1
- YYCITVCFCBWZFO-UHFFFAOYSA-N FC1=C(C(=CC=C1)F)C#CC1=CN=CC2=CC=CC=C12 Chemical compound FC1=C(C(=CC=C1)F)C#CC1=CN=CC2=CC=CC=C12 YYCITVCFCBWZFO-UHFFFAOYSA-N 0.000 description 1
- IEFBLNKQHSEQKR-UHFFFAOYSA-N FC1=C(C(=CC=C1)F)C#CC1=NC2=CC=CC=C2C=C1 Chemical compound FC1=C(C(=CC=C1)F)C#CC1=NC2=CC=CC=C2C=C1 IEFBLNKQHSEQKR-UHFFFAOYSA-N 0.000 description 1
- KXNVDYPPHUVVLA-UHFFFAOYSA-N FC1=C(C(=CC=C1)F)C#CC1=NC=CC2=CC=CC=C12 Chemical compound FC1=C(C(=CC=C1)F)C#CC1=NC=CC2=CC=CC=C12 KXNVDYPPHUVVLA-UHFFFAOYSA-N 0.000 description 1
- UQGCOBGDTQODSV-UHFFFAOYSA-N FC1=C(C(=CC=C1)F)C#CC=1C=C2C(=NC=1)NC=C2 Chemical compound FC1=C(C(=CC=C1)F)C#CC=1C=C2C(=NC=1)NC=C2 UQGCOBGDTQODSV-UHFFFAOYSA-N 0.000 description 1
- YTPHPEPHFLJPGG-UHFFFAOYSA-N FC1=C(C(=CC=C1)F)C#CC=1C=C2C=NN(C2=CC=1)C Chemical compound FC1=C(C(=CC=C1)F)C#CC=1C=C2C=NN(C2=CC=1)C YTPHPEPHFLJPGG-UHFFFAOYSA-N 0.000 description 1
- QLGTUVHTJDPXIT-UHFFFAOYSA-N FC1=C(C(=CC=C1)F)C#CC=1C=CC(=NC=1)N1C=CC=C1 Chemical compound FC1=C(C(=CC=C1)F)C#CC=1C=CC(=NC=1)N1C=CC=C1 QLGTUVHTJDPXIT-UHFFFAOYSA-N 0.000 description 1
- YPPCMVLWCBBKQB-UHFFFAOYSA-N FC1=C(C(=CC=C1)F)C#CC=1C=NC2=CC=CC=C2C=1 Chemical compound FC1=C(C(=CC=C1)F)C#CC=1C=NC2=CC=CC=C2C=1 YPPCMVLWCBBKQB-UHFFFAOYSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 101100237293 Leishmania infantum METK gene Proteins 0.000 description 1
- 101150108651 MAT2 gene Proteins 0.000 description 1
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 102000016397 Methyltransferase Human genes 0.000 description 1
- 108060004795 Methyltransferase Proteins 0.000 description 1
- 101100030361 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) pph-3 gene Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 239000012979 RPMI medium Substances 0.000 description 1
- 101710186153 S-adenosylmethionine synthase 2 Proteins 0.000 description 1
- 101710167557 S-adenosylmethionine synthase isoform type-2 Proteins 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 125000002723 alicyclic group Chemical group 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 229940034982 antineoplastic agent Drugs 0.000 description 1
- 229940111121 antirheumatic drug quinolines Drugs 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 208000036815 beta tubulin Diseases 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000005907 cancer growth Effects 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000004737 colorimetric analysis Methods 0.000 description 1
- 238000009838 combustion analysis Methods 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 125000005265 dialkylamine group Chemical group 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- OAYLNYINCPYISS-UHFFFAOYSA-N ethyl acetate;hexane Chemical compound CCCCCC.CCOC(C)=O OAYLNYINCPYISS-UHFFFAOYSA-N 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 125000001153 fluoro group Chemical class F* 0.000 description 1
- 125000001207 fluorophenyl group Chemical group 0.000 description 1
- 125000001072 heteroaryl group Chemical group 0.000 description 1
- 125000005842 heteroatom Chemical group 0.000 description 1
- 150000003840 hydrochlorides Chemical class 0.000 description 1
- 238000000099 in vitro assay Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- SNHMUERNLJLMHN-UHFFFAOYSA-N iodobenzene Chemical class IC1=CC=CC=C1 SNHMUERNLJLMHN-UHFFFAOYSA-N 0.000 description 1
- 238000006317 isomerization reaction Methods 0.000 description 1
- 150000002537 isoquinolines Chemical class 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 238000001869 matrix assisted laser desorption--ionisation mass spectrum Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 description 1
- 238000007069 methylation reaction Methods 0.000 description 1
- 231100000324 minimal toxicity Toxicity 0.000 description 1
- 238000003032 molecular docking Methods 0.000 description 1
- MEFBJEMVZONFCJ-UHFFFAOYSA-N molybdate Chemical compound [O-][Mo]([O-])(=O)=O MEFBJEMVZONFCJ-UHFFFAOYSA-N 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- AYTAYKXVFZPRAF-UHFFFAOYSA-N n'-(dimethylaminomethylideneamino)-n,n-dimethylmethanimidamide Chemical compound CN(C)C=NN=CN(C)C AYTAYKXVFZPRAF-UHFFFAOYSA-N 0.000 description 1
- PSHKMPUSSFXUIA-UHFFFAOYSA-N n,n-dimethylpyridin-2-amine Chemical compound CN(C)C1=CC=CC=N1 PSHKMPUSSFXUIA-UHFFFAOYSA-N 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- FXSMDDBVGUVRCI-UHFFFAOYSA-N n-methyl-1h-isoquinolin-2-amine Chemical class C1=CC=C2C=CN(NC)CC2=C1 FXSMDDBVGUVRCI-UHFFFAOYSA-N 0.000 description 1
- YCWSUKQGVSGXJO-NTUHNPAUSA-N nifuroxazide Chemical group C1=CC(O)=CC=C1C(=O)N\N=C\C1=CC=C([N+]([O-])=O)O1 YCWSUKQGVSGXJO-NTUHNPAUSA-N 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 150000003222 pyridines Chemical class 0.000 description 1
- JWVCLYRUEFBMGU-UHFFFAOYSA-N quinazoline Chemical compound N1=CN=CC2=CC=CC=C21 JWVCLYRUEFBMGU-UHFFFAOYSA-N 0.000 description 1
- 150000003248 quinolines Chemical class 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 150000003512 tertiary amines Chemical class 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/45—Non condensed piperidines, e.g. piperocaine having oxo groups directly attached to the heterocyclic ring, e.g. cycloheximide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D211/72—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D211/74—Oxygen atoms
- C07D211/76—Oxygen atoms attached in position 2 or 6
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/32—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D207/325—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with substituted hydrocarbon radicals directly attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/73—Unsubstituted amino or imino radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/18—Halogen atoms or nitro radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
- C07D215/42—Nitrogen atoms attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D241/20—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
- C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
- C07D261/08—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/06—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by halogen atoms or nitro radicals
- C07D295/073—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by halogen atoms or nitro radicals with the ring nitrogen atoms and the substituents separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
本发明公开了一种用于治疗癌症的苯乙炔基取代苯和杂环及其应用,其为具有连接到杂环上的N‑烷基氨基或N,N‑二烷基氨基的卤代苯乙炔基取代的杂环,或者含氮杂环连接到苯上的卤代苯乙炔基取代的苯,可作为抑制癌细胞增殖的药物,并且是有用的抗肿瘤剂。
Description
本申请是申请日为2018年6月21日、申请号为201810643008.8、发明名称为“用于治疗癌症的苯乙炔基取代苯和杂环及其应用”的中国专利申请的分案申请。
技术领域
本发明涉及治疗癌症和/或治疗或预防癌症转移的化合物。具体而言,本主题技术涉及带有连接到苯上的含氮杂环的卤代苯乙炔基取代的苯,它们的盐和它们的药物组合物以及其在制备治疗和/或预防癌症药物中的应用。
背景技术
报道了一系列抑制Wnt靶基因如c-myc表达,和抑制在体外和体内抑制结肠癌细胞生长的氟化N,N-二烷基氨基二苯乙烯类似物。参见,例如J Med Chem 2011,54:1288-1297;ACS ChemBiol 2013,8(4):796-803;J Med Chem 2014,57:6083-91;U.S.8,664,276。
此外,对于某些医疗用途而言某些二芳基乙炔是已知的。参见,例如WO2012149049;WO2012149048;WO2010092043;WO2009038759;WO2008073350;和WO2001029011。进而,Tsai的U.S.8,716,355公开了在治疗癌症中的羟基化二苯乙炔和相关化合物,Hadfield等公开了作为抗肿瘤剂的二芳基炔烃的制备和评估。Hadfield等,SynthCommun 1998,28(8):1421-1431。
用于治疗癌症的卤代二芳基乙炔和方法也已有报道。参见公开号为2015-0272908的美国专利申请;Sviripa等,“Halogenated diarylacetylenes repress c-mycexpression in cancer cells”,Bioorg Med Chem Lett 2014,24:3638-40。
然而,对能用于治疗癌症和其他疾病的另外的化合物仍存在不断的需要。
发明内容
本发明的优点包括具有抗肿瘤活性的卤代苯乙炔基取代的苯或杂环化合物及其药物组合物,以及通过施用一种或多种卤代苯乙炔基取代的杂环或其药物组合物在患者中抑制癌症细胞生长和/或治疗癌症的方法。
本公开的一个方面涉及卤代苯乙炔基-取代的苯或杂环,其可用于杀死过度增殖细胞例如癌细胞以治疗人恶性和良性癌症,所述癌症包括但不限于结肠直肠癌(CRC),白血病,乳腺癌,卵巢癌,肺癌,前列腺癌和肝癌。在本发明的该方面中,提供了某些对癌细胞具有抗肿瘤活性的卤代苯乙炔基取代的杂环。本发明的卤代苯乙炔基取代的苯和杂环包括根据式(I)、(II)和(III)的化合物或其药学上可接受的盐:
其中X1至X5各自独立地表示H、低级烷基、烷氧基例如低级烷氧基、卤素和/或NR1R2,其中R1和R2各自独立地表示H或低级烷基,n为1或0,并且当n为1时,Y1至Y4各自独立地表示H、低级烷基或烷氧基、或NR1R2。杂环表示可以未被取代或被一个或多个低级烷基、或烷氧基例如低级烷氧基、和/或一个或多个卤素取代的杂环;其中杂环选自氧代哌啶、吗啉、哌嗪、N-甲基哌嗪、N-吡咯和2,5-二甲基-N-吡咯、喹啉、异喹啉、吲哚、吲唑、萘啶和吡啶基;并且Y5表示一个或多个NR1R2,和/或一个或多个可以相同或不同的卤素。
式(I)、(II)或(III)的卤代苯乙炔基取代的苯或杂环或其药学上可接受的盐可以与药学上可接受的载体一起包含在药物组合物中。
本发明的另一方面涉及上述卤代苯乙炔基取代的苯或杂环在制备治疗和/或预防癌症药物中的应用,例如在制备抑制癌细胞生长和/或抑制哺乳动物(例如人)的肿瘤生长药物或治疗与过度增殖细胞相关的疾病药物中的应用。在本发明的该方面的一个实施方式中,将有效量的一种或多种卤代苯乙炔基取代的苯或杂环、其药用盐和/或药物组合物施用于需要治疗癌症的患者,该有效量足以在患者中治疗/抑制癌细胞生长。
在本发明的该方面的一个实施方式中,将治疗有效量的一种或多种卤代苯乙炔基取代的苯和杂环、其药用盐和/或药物组合物施用于患有结直肠癌的患者。在另一个实施方式中,将治疗有效量的一种或多种带有连接到苯上的含氮杂环的卤代苯乙炔基取代的苯和一种或多种卤代含氮苯乙炔基取代的杂环、其药用盐和/或其药物组合物施用于患有肝癌或前列腺癌的患者。
从以下详细描述,本发明的其他优点对本领域技术人员来说将变得显而易见,其中通过仅说明完成本发明所考虑的最佳模式仅示出和描述了本发明的优选实施方式。如将认识到的,本发明能够具有其他和不同的实施方式,并且其若干细节能够在各种明显的方面进行修改,所有这些都不脱离本发明。因此,附图和说明书本质上被认为是说明性的,而不是限制性的。
附图说明
图1显示2,6-二氟-4’-(N,N-二甲氨基)二苯乙烯(图中标“1”)和2,6-二氟苯基-4’-(N,N-二甲氨基)苯基乙炔(图中标“2”)的结构式。图1还说明了杂环取代的苯乙炔基苯(图中标“4”)和苯乙炔基取代的杂环(图中标“5”)和(图中标“7”)的合成过程。图中a表示:杂环取代的苯基碘,iPr2EtN,Pd(PPh3)4,CuI,H2O,80℃;b表示:杂芳基碘,iPr2EtN,Pd(PPh3)4,CuI,H2O,80℃;c表示:氯取代的杂芳基碘,iPr2EtN,Pd(PPh3)4,CuI,H2O,75℃,然后是单烷基胺或二烷基胺,THF,130℃,2-3h,压力管;d表示:氟化杂芳基碘,iPr2EtN,Pd(PPh3)4,CuI,H2O,80℃。
图2A是显示4-((2,6-二氟苯基)乙炔基)-N,N-二甲基苯胺(图中以“2”表示),4-((2,6-二氟苯基)乙炔基)-N,N-二甲基异喹啉-1-胺(图中以“5nn”表示)和4-((2,6-二氟苯基)乙炔基)-N-甲基异喹啉-1-胺(图中以“5oo”表示)对300nM浓度的LS174T细胞中cyclinD1和p21Wif1/Cip1表达的影响的蛋白质印迹。
图2B是在LS174T细胞增殖试验中化合物“2”、“5nn”和“5oo”的剂量反应图。对“2”、“5nn”和“5oo”而言IC50分别为25.1±1.3,11.8±1.5和4.2±0.2nM。
具体实施方式
本发明涉及卤代苯乙炔基取代的苯和杂环化合物、它们的盐和它们的药物组合物,以及一种或多种卤代苯乙炔基取代的苯和杂环、其药用盐或其药物组合物在制备抑制癌细胞生长和/或治疗癌症药物中的应用。已发现在一个芳环中具有至少一个、优选两个卤素取代基,以及在芳基或杂芳基环对位具有胺(例如N-甲氨基或N,N-二甲氨基)的卤代苯乙炔基取代的苯和杂环,通过抑制c-myc和诱导细胞周期蛋白-依赖性激酶抑制剂-1(即p21Wif1/Cip1)来抑制LS174T结肠癌细胞的增殖。这样的化合物和组合物可用作抗肿瘤剂。
本发明的卤代苯乙炔基取代的苯和杂环在卤代苯乙炔基取代的苯和杂环的苯或杂环上包含至少一个胺基,例如伯、仲或叔胺。这样的化合物可用作抗肿瘤剂并可以由下式或其药学上可接受的盐表示:
X1至X5的取代基各自独立地表示H、低级烷基或烷氧基例如低级烷氧基、卤素和/或NR1R2,其中R1和R2各自独立地表示H或低级烷基。在本发明的一个实施方式中,X1至X5中的至少一个是卤素并且其余的X1至X5表示H、低级烷基或低级烷氧基。在本发明的另一个实施方式中,X1至X5至少一个是NR1R2。卤素基团是指F、Cl、Br或I。优选取代基X1至X5包括至少两个卤素基团,例如F和/或Cl。在本发明的一个实施方式中,X1至X5是卤素基团,例如两个F基团,两个Cl基团或一个F和一个Cl基团。
变量n可以为1或0。当n为1时,式(I)的卤代苯乙炔基取代的苯可以由以下式(II)表示。
对于式(II),Y1至Y4各自独立地表示H、低级烷基或NR1R2,其中R1和R2各自独立地表示H或低级烷基。
当n是0时,式(I)可以由以下式(III)的卤代苯乙炔基取代的杂环表示。
式(II)和(III)的X1至X5的取代基如式(I)所述,包括其所有组合。对于式(I),(II)和(III)中的每一个,杂环表示有杂原子的环。例如,杂环表示可以选自氧代哌啶,吗啉,哌嗪,N-甲基哌嗪,N-吡咯和2,5-二甲基-N-吡咯,喹啉,异喹啉,吲哚,吲唑,萘啶和吡啶基中的杂环。对于式(I),(II)和(III)中的每一个,杂环可以未被取代或被一个或多个低级烷基或烷氧基(例如低级烷氧基)和/或一个或多个卤素取代。在式(I),(II)和(III)每一个中变量Y5代表一个或多个NR1R2,和/或一个或多个可以相同或不同的卤素,即每个NR1R2基团可以具有相同或不同的R1和R2,其中R1和R2各自独立地表示H或低级烷基,和/或具有一个或多个相同或不同卤素的杂环。在本发明的一个实施方式中,式(I),(II)和(III)每一个中的Y5表示一个或多个NR1R2。在本发明的另一个实施方式中,式(I),(II)和(III)每一个中的Y5表示一个或多个卤素。例如,对于式(III),X1至X5中的至少一个为NR1R2并且杂环表示具有至少一个卤素且优选两个卤素基团(例如氟和/或氯基团)的吡啶基环。
术语“低级烷基”包括饱和脂肪族基团,包括具有1至约10个碳(C1-C10)的直链烷基、支链烷基、环烷(脂环)基、烷基取代的环烷基和环烷基取代的烷基,例如在其主链结构中具有1至约6个碳原子(C1-C6)。在本发明的一个方面中,低级烷基具体包括甲基、乙基、丙基、异丙基、正丁基等。
本发明的卤代苯乙炔基取代的苯和杂环的实施方式包括其中X1至X5中的至少两个是卤素基团,例如其中X1至X5中的至少两个是(i)氟和氯,(ii)两个氟,(iii)两个氯,并且其中R1和R2都是低级烷基(例如甲基、乙基或丁基)。优选地,X1和/或X5是卤素基团,例如苯乙炔基取代的苯和杂环在相对于炔键的邻位具有一个或两个卤素取代基,并且X1至X4是H或低级烷基或烷氧基。在一些实施方式中,卤代苯乙炔基取代的苯和杂环包括其中Y3是NR1R2且Y1、Y2、Y4和Y5独立地表示H、低级烷基或NR1R2的化合物或其药学上可接受的盐。在其他实施方式中,Y3是NR1R2,且Y1、Y2、Y4和Y5独立地表示H或低级烷基,例如Y1、Y2、Y4和Y5表示H。在又一些实施方式中,R1或R2中的至少一个是低级烷基。
本发明的药物组合物包括药学上可接受的载体和一种或多种根据式(I)、(II)或(III)的化合物或式(I)、(II)或(III)化合物药学上可接受的盐。
在本发明的一个方面中,式(I)、(II)或(III)的化合物,其药学上可接受的盐或其药学上可接受的组合物用于治疗癌症。治疗时给需要这种治疗的患者施用有效量的一种或多种卤代苯乙炔基取代的杂环、其药用盐或其药物组合物。该方法的实施方式包括其中所治疗的癌症选自结直肠癌、白血病、乳腺癌、卵巢癌、肺癌、前列腺癌和肝癌。
在关注结直肠癌机制的研究过程中,我们使用化学生物学来探测调节基因表达的细胞信号传导事件。这一过程中的关键步骤选择性靶向提供了开发治疗剂以治疗这些癌症的潜力。例如,我们报道了2’,6’-二卤代苯乙烯基苯胺(1)(图1)抑制Wnt靶基因如c-myc的表达,以及在体外和体内抑制结肠癌LS174T细胞生长。参见例如J Med Chem 2011,54:1288-1297;ACS ChemBiol2013,8(4):796-803;J Med Chem 2014,57,6083-91。我们确定这种试剂专门靶向低聚酶的催化子单元,即甲硫氨酸S-腺苷转移酶-2(MAT2),其将S-腺苷甲硫氨酸(SAM)提供给调节性甲基转移酶并且在选择的一组癌症中上调。我们进一步确定这些2’,6’-二卤代苯乙烯基苯胺(1)的杂环变体具有最小的总毒性,而没有所期望的人类ether-à-go-go-相关蛋白(hERG)活化,合理的生物利用度和药代动力学。根据需要,这些基于1,2-二苯乙烯的试剂不影响甲硫氨酸S-腺苷转移酶-1(MAT1),其作为其他细胞需要所必需的SAM的主要来源。与其他MAT2A抑制剂的最新报道不同,我们还在使用结直肠癌细胞的异种移植模型中证实了体内效力。
关于可能潜在地使将来的药代动力学和药效学研究复杂化的二苯乙烯1中的热或光化学E/Z异构化的担忧导致合成和评价类似的二芳基乙炔2(图1)。根据二苯乙烯1的SAR研究,我们发现在一个苯环上带有N,N-二甲基氨基且在另一个苯环上带有一个或优选两个邻位取代的氟或氯基团的二芳基乙炔2,在结直肠癌LS174T细胞增殖试验中保持了体外的效力。二芳基乙炔2还具有对心脏钾hERG通道影响最小的期望性质。分子停靠(docking)研究表明,二芳基乙炔和杂环对应物,如它们的二苯乙烯对应物,靶向MAT2的催化子单元(MAT2A)。
为了获得相对于少量溶于水的4-((2,6-二氟苯基)乙炔基)-N,N-二甲基苯胺(2)改进的效力、溶解度和生物利用度,我们进行了另外的结构-活性研究。最初的工作集中在2中的N,N-二甲基氨基的替换,用杂环代替在杂环取代的二苯基乙炔4中的N,N-二甲基氨基(图1)。2,6-二氟苯基乙炔(3)与4-碘苯基取代的杂环的Sonogashira偶联提供了氧代哌啶基、吗啉基、N-甲基哌嗪基,N-吡咯基和2,5-二甲基-N-吡咯基类似物4a-4e(表1)。在细胞增殖测定中N-吡咯基类似物4d在1μM浓度下显示在与4-((2,6-二氟苯基)乙炔基)-N,N-二甲基苯胺(2)相当的活性,但在100nM下显示显著降低的活性。
下表1提供了如图1中化合物4(例如式(II))所示的本发明的某些杂环取代的苯乙炔基苯在各种浓度下对结肠癌LS174T细胞的增殖的抑制(%)。表1还提供了2,6-二氟苯基-4’-(N,N-二甲基氨基)苯基乙炔(2)这样的数据用于比较。
表1
化合物 | C-4'取代基 | 10μM | 1μM | 100nM |
2<sup>a</sup> | N,N-二甲基氨基 | 99.5±0.1 | 85.2±0.5 | |
4a | 1-哌啶基-2-酮 | 68.1±6.9 | 6.4±11.0 | |
4b | N-吗琳基 | 32.1±9.8 | 13.0±2.5 | |
4c | N'-甲基-N-哌嗪基 | 99.6±0.2 | 19.9±18.2 | |
4d | N-吡咯基 | 96.7±1.9 | 77.5±9.2 | 11.0±18.1 |
4e | 2,5-二甲基-N-吡咯基 | 78.8±4.8 | 20.9±10.0 |
a,数据来自Sviripa等,“Halogenated diarylacetylenes repress c-mycexpression in cancer cells”,Bioorg Med Chem Lett 2014,24:3638-40。
由于二苯乙烯系列中的杂环变体显示出改善的溶解度和最小的hERG活化,所述变体其中1中的N,N-二甲基苯胺环(图1)被N,N-二甲基氨基吡啶或N,N-二甲基氨基嘧啶环取代,接下来我们着重于用如在图1中的化合物5(例如式(III))所示的苯乙炔基取代的杂环中的杂环代替二芳基乙炔系列中的N,N-二甲基苯胺环。2,6-二氟苯基乙炔与碘取代的杂环的Sonogashira偶联提供了大部分这些类似物(表2)。在一些情况下,例如5nn-5oo的合成,优选将2,6-二氟苯基乙炔与1-氯-4-碘异喹啉偶联,随后利用亲核芳族取代反应用仲胺取代氯基。另一种方法涉及2,6-二氟苯基乙炔与1-氨基-4-碘异喹啉的偶联,得到4-((2,6-二氟苯基)乙炔基)异喹啉-1-胺,随后通过中间体1,2,4-三唑使用1,2-双[(二甲基氨基)亚甲基]肼进行胺基的N,N-二甲基化,但后一过程的总收率低于亲核芳族取代反应中的收率。如表2中所概括的,使用这些方法,我们合成了2,6-二氟苯基乙炔基取代的杂环,包括吡啶5a-5c,吡嗪5d,吲哚5e-5f,1H-吲唑5g-5k,1H-吡咯并[2,3-b]吡啶5l,喹啉5m-5ff,异喹啉5gg-5oo,1,6-萘啶5qq和喹唑啉5rr。
下表2提供了本发明的由图1中化合物5(例如式(III))所示的2,6-二氟苯基乙炔基取代的杂环在各种浓度下抑制结肠癌LS174T细胞的细胞增殖(%)。
表2
a,2,6-二氟苯基乙炔基的连接位置;b,来自Sviripa等,“Halogenateddiarylacetylenes repress c-myc expression in cancer cells”,Bioorg Med ChemLett 2014,24:3638-40的数据;c,如盐酸盐测试。
在10μM浓度下,表2中的大部分2,6-二氟苯基乙炔基取代的杂环5显示出对LS174T结肠癌细胞增殖试验的有效作用,并且在1μM浓度下,几种吡啶5b和5c、一种吲哚5f、两种1H-吲唑5i和5k、两种喹啉5x和5ff以及四种异喹啉5mm-5oo和5qq显示大于75%的抑制。在2,6-二氟苯乙炔基取代的杂环5中突出的两个侯选物为4-((2,6-二氟苯基)乙炔基)-N,N-二甲基异喹啉-1-胺(5nn)和4-((2,6-二氟苯基)乙炔基)-N-甲基异喹啉-1-胺(5oo)。另外,几种二氟化苯乙炔基取代的杂环如5pp和5qq提供了完全水溶性的盐酸盐。总之,我们鉴定了具有超过母体化合物4-((2,6-二氟苯基)乙炔基)-N,N-二甲基苯胺(2)的效力和/或水溶性的杂环变体5。
使用钼酸盐比色法测定磷酸盐的MAT2A抑制试验的变异性使得测定细胞周期抑制成为评估二芳基乙炔效力的优选分析工具。我们测试了这些杂环取代的二苯基乙炔4(表1)和氟化苯乙炔基取代的杂环5(表2)对LS174T结肠癌细胞增殖的影响。如蛋白质印迹(图2A)所示,最活跃的化合物2、5nn和5oo在300nM浓度下抑制细胞周期蛋白D1的表达,并且如同对细胞周期抑制剂所预期的那样,同时诱导p21Wif1/Cip1。与其中N-甲基苯胺基和N,N-二甲基苯胺基类似物2在抑制LS174T细胞增殖中显示相当活性(即,2,IC5025.1nM)的二芳基乙炔系列不同,苯乙炔基取代的杂环中的N-甲基化模式表明N-甲基氨基异喹啉类似物5oo(IC504.2nM)比N,N-二甲基氨基异喹啉类似物5nn(IC50 11.8nM)更有效(图2B)。总之,苯乙炔基取代的杂环化合物5通过改变c-myc的表达并由此诱导p21Wif1/Cip1来抑制LS174T结肠癌细胞的增殖。这些结果与使用卤代二苯乙烯和二芳基乙炔的先前发现一致,并且鉴于在5中相对于二苯乙烯不存在异构化,提高的效力和改善的物理性质(例如水溶性)表明苯乙炔基取代的杂环通过类似机制抑制结肠癌增殖。对这些苯乙炔基取代的杂环的进一步研究是正在进行的研究的主题。
我们还关注由图1中的化合物7代表的苯乙炔基取代的杂环,例如式(III)。4-氨基,4-N-甲基氨基或4-N,N-二甲基氨基乙炔与碘取代的氟代杂环的Sonogashira偶联提供了这些类似物7(表3)。
表3
化合物 | 杂环 | 苯环 | 300nM | 100nM | 30nM |
7a | 2,6-二氟-4-吡啶 | C<sub>6</sub>H<sub>5</sub> | 12.2±7.1 | 24.7±3.7 | 5.3±7.9 |
7b | 2,6-二氟-4-吡啶 | C<sub>6</sub>H<sub>4</sub>-4-NH<sub>2</sub> | 36.2±4.5 | 30.5±2.2 | 11.4±7.8 |
7c | 2,6-二氟-4-吡啶 | C<sub>6</sub>H<sub>4</sub>-4-NHCH<sub>3</sub> | 62.6±1.3 | 49.5±5.5 | 20.3±5 |
7d | 2,6-二氟-4-吡啶 | C<sub>6</sub>H<sub>4</sub>-4-N(CH<sub>3</sub>)<sub>2</sub> | 60.6±5.2 | 20.4±0.5 | 16.7±7.7 |
在300nm浓度下,表3中的几种2,6-二氟-4-吡啶基乙炔基取代的苯7显示出对LS174T结肠癌细胞增殖试验的有效作用。这种体外试验的效力并不是促使化合物向临床研究前进的唯一标准,另外的研究、实验和计算表明,这些化合物具有最小的毒性和改善的ADME参数。使用体内异种移植研究,几种这些化合物7也显示出非常有希望的活性。
实施例
以下实施例旨在进一步说明本发明的某些优选实施方式,本质上不是限制性的。本领域技术人员将认识到或能够确定使用不超过常规实验的本文所述的特定物质和程序的许多等同物。
材料
化学品购自Sigma Aldrich或Fisher Scientific或根据文献程序合成。除非另有说明,否则来自商业供应商的溶剂不经进一步纯化而使用。在Varian(1H,400MHz;13C,100Mz)和Bruker(1H,700MHz;13C,176Mz)仪器上测定核磁共振谱。在LTQ-OrbitrapVelos质谱仪(Thermo Fisher Scientific,Waltham,MA,USA)上记录高分辨率电喷雾电离(ESI)质谱。FT分辨率定为100,000(400m/z)。使用流速为5μL/min的注射泵通过直接输注引入样品。使用DHB(2,5-二羟基苯甲酸)基质,在Bruker Utraflexstreme飞行时间质谱仪(Billerica,MA)上获得MALDI质谱。通过Atlantic Microlabs,Inc.,Norcross,GA的燃烧分析确定了化合物的纯度。除非另有说明,将化合物在制备层Merck硅胶F254上层析。
用于2,6-二氟苯基乙炔与芳基碘化物或杂芳基碘化物的Sonogashira偶联的一般程序。
向在7mL水中的2.1mmol芳基碘化物或杂芳基碘化物、3mmol二异丙基乙基胺、0.02mmol Pd(PPh3)4和0.02mmol CuI的混合物中加入2mmol 2,6-二氟苯基乙炔。在75℃搅拌混合物1-2小时。将混合物冷却,通过过滤或使用二氯甲烷萃取收集产物。产物4或5如下所述通过重结晶和/或色谱纯化。
1-(4-((2,6-二氟苯基)乙炔基)苯基)哌啶-2-酮(4a).收率75%;使用1:10甲醇-二氯甲烷的制备层色谱法(Rf=0.52);mp 148-150℃。1H NMR(400MHz,DMSO-d6)δ7.58(d,J=8.5Hz,2H),7.56-7.47(m,1H),7.40(d,J=8.5Hz,2H),7.26(t,J=8Hz,2H),3.64(t,J=5.6Hz,2H),2.42(t,J=6.3Hz,2H),1.94-1.77(m,4H)。13C NMR(101MHz,DMSO-d6)δ169.01,162.01(dd,J=5.2,251.5Hz,2C),144.53,131.78(2C),131.39(t,J=10Hz),126.19(2C),118.35,111.94(dd,J=5.3,18.2Hz,2C),100.77(t,J=19.8Hz),98.63(t,J=3.1Hz),75.77,50.29,32.70,22.91,20.79。HRMS(ESI)理论计算C19H16F2NO[MH+]:312.1194。实际测定:312.1195。理论分析计算C19H15F2NO:C,73.30;H,4.86;N,4.50。实际测定:C,73.04;H,4.85;N,4.52。
4-(4-((2,6-二氟苯基)乙炔基)苯基)吗啉(4b).收率67%;使用1:5乙酸乙酯-己烷的柱色谱法并从己烷重结晶;mp 144-145℃。1H NMR(400MHz,DMSO-d6)δ7.53-7.44(m,1H),7.42(d,J=8.9Hz,2H),7.22(t,J=7.9Hz,2H),6.98(d,J=8.8Hz,2H),3.73(t,J=4.8Hz,4H),3.2(t,J=4.9Hz,4H)。13C NMR(101MHz,DMSO-d6)δ161.85(dd,J=5.3,250.6Hz,2C),151.36,132.57(2C),130.51(t,J=10.1Hz),114.35(2C),111.89(dd,J=5.4,250.6Hz,2C),110.38,101.55(t,J=19.9Hz),100.09(t,J=3Hz),74.28,65.91(2C),47.21(2C)。HRMS(ESI)理论计算C18H16F2NO[MH+]:300.1194。实际测定:300.1195。理论分析计算C18H15F2NO:C,72.23;H,5.05;N,4.68。实际测定:C,71.98;H,5.09;N,4.72。
1-(4-((2,6-二氟苯基)乙炔基)苯基)-4-甲基哌嗪(4c).收率60%,用1:10甲醇-二氯甲烷的制备层色谱法(Rf=0.43);mp 126-128℃。1H NMR(400MHz,DMSO-d6)δ7.53-7.42(m,1H),7.39(d,J=8.8Hz,2H),7.22(t,J=7.9Hz,2H),6.96(d,J=8.9Hz,2H),3.24(t,J=4.9Hz,4H),2.43(t,J=5.1Hz,4H),2.21(s,3H)。13C NMR(101MHz,DMSO-d6)δ161.82(dd,J=5.4,250.6Hz,2C),151.21,132.56(2C),130.43(t,J=10.1Hz),114.49(2C),111.8(dd,J=5.3,18.2Hz,2C),109.85,101.59(t,J=19.9Hz),100.22(t,J=3Hz),74.17,54.35(2C),46.87(2C),45.73。HRMS(ESI)理论计算C19H19F2N2[MH+]:313.1511。实际测定:313.1489。理论分析计算C19H18F2N2:C,73.06;H,5.81;N,8.97。实际测定:C,72.84;H,5.75;N,8.89。
1-(4-((2,6-二氟苯基)乙炔基)苯基)-1H-吡咯(4d).收率79%;用1:5乙酸乙酯-己烷的制备层色谱法(Rf=0.68);mp 122-124℃。1H NMR(400MHz,DMSO-d6)δ7.76-7.61(m,4H),7.60-7.49(m,1H),7.48(t,J=2.2Hz,2H),7.32-7.17(m,2H),6.31(t,J=2.2Hz,2H)。13C NMR(101MHz,DMSO-d6)δ162.01(dd,J=5,251.5Hz,两个C),140.3,132.98(2C),131.36(t,J=10.1Hz),119.15(2C),118.92(2C),117.61,111.93(dd,J=5.4,18.3Hz,2C),111.19(2C),100.91(t,J=19.7Hz),98.45(t,J=3Hz),76.09。HRMS(ESI)理论计算C18H12F2N[MH+]:280.0932。实际测定:280.0924。理论分析计算C18H11F2N:C,77.41;H,3.97;N,5.02。实际测定:C,77.20;H,4.21;N,4.89。
1-(4-((2,6-二氟苯基)乙炔基)苯基)-2,5-二甲基-1H-吡咯(4e).收率84%;用1:10乙酸乙酯-己烷的柱色谱法;mp 124-126℃。1H NMR(400MHz,DMSO-d6)δ7.71(d,J=8.4Hz,2H),7.62-7.51(m,1H),7.36(d,J=8.5Hz,2H),7.30-7.25(m,2H),5.83(s,2H),2.00(s,6H)。13C NMR(101MHz,DMSO-d6)δ162.07(dd,J=5.2,251.8Hz,2C),139.2,132.43(2C),131.66(t,J=10.2Hz),128.49(2C),127.55(2C),120.42,111.96(dd,J=5.3,19Hz,2C),106.48(2C),100.69(t,J=19.7Hz),98.05(t,J=3Hz),76.71,12.86(2C)。HRMS(ESI)理论计算C20H16F2N[MH+]:308.1245。实际测定:308.1229。理论分析计算C20H15F2N:C,78.16;H,4.92;N,4.56。实际测定:C,77.91;H,5.03;N,4.42。
6-((2,6-二氟苯基)乙炔基)-N,N-二甲基吡啶-3-胺(5a).收率68%;用1:2乙酸乙酯-己烷的制备层色谱法(Rf=0.53);mp 120-122℃。1H NMR(400MHz,DMSO-d6)δ8.13(d,J=3Hz,1H),7.55-7.46(m,1H),7.44(d,J=8.7Hz,1H),7.29-7.2(m,2H),7.06(dd,J=3.1,8.8Hz,1H),3(s,6H)。13C NMR(101MHz,DMSO-d6)δ162.01(dd,J=5.3,251.2Hz,2C),145.52,134.97,130.95(t,J=10.1Hz),127.79,127.47,117.6,111.96(dd,J=5.3,18.2Hz,2C),101.11(t,J=19.8Hz),99.79(t,J=3.1Hz),72.88,39.33(2C)。HRMS(ESI)理论计算C15H13F2N2[MH+]:259.1041。实际测定:259.1023。理论分析计算C15H12F2N2:C,69.76;H,4.68;N,10.85。实际测定:C,69.61;H,4.85;N,10.83。
5-((2,6-二氟苯基)乙炔基)-N,N-二甲基吡啶-2-胺(5b).收率79%;用1:5乙酸乙酯-己烷的制备层色谱法(Rf=0.41);mp 110-112℃。1H NMR(700MHz,DMSO-d6)δ8.29(d,J=2.1Hz,1H),7.64(dd,J=2.4,8.9Hz,1H),7.53-7.43(m,1H),7.22(t,J=7.9Hz,2H),6.68(d,J=8.9Hz,1H),3.08(s,6H)。13C NMR(176MHz,DMSO-d6)δ161.74(dd,J=5.2,250.7Hz,2C),158.12,150.93,139.51,130.56(t,J=10.1Hz),111.81(dd,J=3.9,20.2Hz,2C),105.54,104.57,101.48(t,J=19.8Hz),98.02(t,J=3Hz),76.11,37.52(2C)。HRMS(ESI)理论计算C15H13F2N2[MH+]:259.1041。实际测定:259.1023。理论分析计算C15H12F2N2:C,69.76;H,4.68;N,10.85。实际测定:C,69.49;H,4.81;N,10.76。
5-((2,6-二氟苯基)乙炔基)-2-(1H-吡咯-1-基)吡啶(5c).收率66%,用1:5乙酸乙酯-己烷的制备层色谱法(Rf=0.47)并从abs.乙醇中重结晶;mp121-123℃。1H NMR(700MHz,DMSO-d6)δ8.63(d,J=2.2Hz,1H),8.12(dd,J=2.3,8.6Hz,1H),7.81(d,J=8.6Hz,1H),7.73(t,J=2.3Hz,2H),7.62-7.51(m,1H),7.28(t,J=8Hz,2H),6.34(t,J=2.3Hz,2H)。13C NMR(176MHz,DMSO-d6)δ162.02(dd,J=5,252Hz,2C),151.04,150.19,141.74,131.8(t,J=10.1Hz),118.35(2C),114.63,112.07(m,4C),111.27,100.54(t,J=19.7Hz),95.5(t,J=2.9Hz),78.6。HRMS(ESI)理论计算C17H11F2N2[MH+]:280.0885。实际测定:280.0886。理论分析计算C17H10F2N2:C,72.85;H,3.60;N,10.00。实际测定:C,72.74;H,3.69;N,9.84。
5-((2,6-二氟苯基)乙炔基)-N,N-二甲基吡嗪-2-胺(5d).收率73%,用1:10乙酸乙酯-己烷的柱色谱法;mp 137-138℃。1H NMR(400MHz,DMSO-d6)δ8.3(d,J=1.4Hz,1H),8.19(d,J=1.4Hz,1H),7.52(m,1H),7.25(t,J=8Hz,2H),3.13(s,6H)。13C NMR(101MHz,DMSO-d6)δ161.93(dd,J=251.5,5.2Hz,2C),152.96,145.35,131.25(t,J=10.1Hz),130.64,123.25,111.93(dd,J=5.2,18.6Hz,2C),100.85(t,J=19.8Hz),97.31(t,J=3Hz),75.74,37.2(2C)。HRMS(ESI)理论计算C14H12F2N3[MH+]:260.0994。实际测定:260.0994。理论分析计算C14H11F2N3:C,64.86;H,4.28;N,16.21。实际测定:C,64.63;H,4.25;N,16.39。
5-((2,6-二氟苯基)乙炔基)-1H-吲哚(5e).收率63%;用1:5乙酸乙酯-己烷的制备层色谱法(Rf=0.44);mp 131-133℃。1H NMR(400MHz,DMSO-d6)δ11.4(s,1H),7.82(s,1H),7.52-7.44(m,3H),7.27(dd,J=1.6,8.5Hz,1H),7.23(t,J=8Hz,2H),6.51-6.49(m,1H)。13C NMR(101MHz,DMSO-d6)δ161.94(dd,J=5.4,250.5Hz,2C),136.08,130.44(t,J=10.1Hz),127.63,126.95,124.24,124.18,112.06,111.81(dd,J=5.4,18.3Hz,2C),111.35,101.69(t,J=19.7Hz),101.59,101.49(t,J=3Hz),73.26。HRMS(ESI)理论计算C16H10F2N[MH+]:254.0776。实际测定:254.0760。理论分析计算C16H9F2N:C,75.88;H,3.58;N,5.53。实际测定:C,76.07;H,3.63;N,5.41。
5-((2,6-二氟苯基)乙炔基)-1-甲基-1H-吲哚(5f).收率76%;用1:2乙酸乙酯-己烷的柱色谱法;mp 100-102℃。1H NMR(400MHz,DMSO-d6)δ7.82(d,J=1.6Hz,1H),7.55-7.45(m,2H),7.43(d,J=3Hz,1H),7.33(dd,J=1.6,8.5Hz,1H),7.24(t,J=7.9Hz,2H),6.5(d,J=2.6Hz,1H),3.82(s,3H)。13C NMR(101MHz,DMSO-d6)δ161.94(dd,J=5.4,250.6Hz,2C),136.45,131.28,130.51(t,J=10.1Hz),127.96,124.41,124.24,111.83(dd,J=5.3,19.6Hz,2C),111.45,110.42,101.63(t,J=20.0Hz),101.28(t,J=3Hz),100.92,73.52,32.63。HRMS(ESI)理论计算C17H12F2N[MH+]:268.0932。实际测定:268.0917。理论分析计算C17H11F2N:C,76.39;H,4.15;N,5.24。实际测定:C,76.17;H,4.31;N,5.04。
4-((2,6-二氟苯基)乙炔基)-1H-吲唑(5g).收率71%,用1:2乙酸乙酯-己烷的柱色谱法;mp178-179℃。1H NMR(400MHz,DMSO-d6)δ13.45(s,1H),8.11(s,1H),7.69(d,J=7.8Hz,1H),7.63-7.52(m,1H),7.47-7.37(m,2H),7.3(t,J=8Hz,2H)。13C NMR(101MHz,DMSO-d6)δ162.05(dd,J=5.2,251.8Hz,2C),139.64,132.2,131.67(t,J=10.2Hz),126.16,124.5,123.35,112.98,112.22,112.05(dd,J=5.3,18.2Hz,2C),100.9(t,J=19.7Hz),96.74(t,J=3Hz),79.12。HRMS(ESI)理论计算C15H9F2N2[MH+]:255.0728。实际测定:255.0712。理论分析计算C15H8F2N2:C,70.86;H,3.17;N,11.02。实际测定:C,70.60;H,3.25;N,10.92。
5-((2,6-二氟苯基)乙炔基)-1H-吲唑(5h).收率25%,用1:2乙酸乙酯-己烷的制备层色谱法(Rf=0.63);mp 193-195℃。1H NMR(700MHz,DMSO-d6)δ13.34(s,1H),8.15(s,1H),8.08(s,1H),7.62(d,J=8.6Hz,1H),7.54-7.45(m,2H),7.25(t,J=7.9Hz,2H)。13C NMR(176MHz,DMSO-d6)δ162.01(dd,J=5.2,251Hz,2C),139.52,134.15,130.94(t,J=10.1Hz),128.85,124.98,122.82,112.96,111.88(dd,J=3.8,20.2Hz,2C),110.94,101.24(t,J=19.8Hz),100.03(t,J=3Hz),74.15。HRMS(ESI)理论计算C15H9F2N2[MH+]:255.0728。实际测定:255.0727。理论分析计算C15H8F2N2:C,70.86;H,3.17;N,11.02。实际测定:C,70.64;H,3.22;N,11.09。
6-((2,6-二氟苯基)乙炔基)-1H-吲唑(5i).收率87%,用1:1乙酸乙酯-己烷的柱色谱法;mp192-194℃。1H NMR(400MHz,DMSO-d6)δ13.31(s,1H),8.15(s,1H),7.85(d,J=8.3Hz,1H),7.77(s,J=1.2Hz,1H),7.6-7.48(m,1H),7.33-7.21(m,3H)。13C NMR(101MHz,DMSO-d6)δ162.09(dd,J=5.2,251.5Hz,2C),139.31,133.87,131.44(t,J=10.2Hz),123.20,123.04,121.37,118.43,113.63,111.99(dd,J=5.3,19Hz,2C),100.94(t,J=19.7Hz),99.67(t,J=3.1Hz),75.66。HRMS(ESI)理论计算C15H9F2N2[MH+]:255.0728。实际测定:255.0712。理论分析计算C15H8F2N2:C,70.86;H,3.17;N,11.02。实际测定:C,70.61;H,3.06;N,10.88。
5-((2,6-二氟苯基)乙炔基)-1-甲基-1H-吲唑(5j).收率47%;用1:5乙酸乙酯-己烷的制备层色谱法(Rf=0.31);mp 107-109℃。1H NMR(700MHz,DMSO-d6)δ8.12(d,J=0.9Hz,1H),8.06(s,1H),7.73(d,J=8.7Hz,1H),7.55(dd,J=1.5,8.7Hz,1H),7.53-7.48(m,1H),7.25(t,J=7.9Hz,2H),4.08(s,3H)。13C NMR(176MHz,DMSO-d6)δ162.01(dd,J=5.2,251.0Hz,2C),139.19,133.06,130.98(t,J=10Hz),128.78,125.17,123.39,113.04,111.89(dd,J=3.8,20.2Hz,2C),110.54,101.2(t,J=19.8Hz),99.87(t,J=3Hz),74.38,35.53。HRMS(ESI)理论计算C16H11F2N2[MH+]:269.0885。实际测定:269.0885。理论分析计算C16H10F2N2:C,71.64;H,3.76;N,10.44。实际测定:C,71.41;H,3.75;N,10.53。
6-((2,6-二氟苯基)乙炔基)-1-甲基-1H-吲唑(5k).收率75%;用1:5乙酸乙酯-己烷的制备层色谱法(Rf=0.35);mp 117-119℃。1H NMR(400MHz,DMSO-d6)δ8.12(s,1H),7.99(s,1H),7.83(d,J=8.4Hz,1H),7.63-7.47(m,1H),7.32-7.2(m,3H),4.09(s,3H)。13C NMR(101MHz,DMSO-d6)δ162.09(dd,J=5.2,251.6Hz,2C),139.09,132.68,131.44(t,J=10.2Hz),123.56,123.20,121.49,118.42,113.46,111.94(dd,J=5.2,18.6Hz,2C),100.88(t,J=19.7Hz),99.65(t,J=3Hz),75.81,35.58。HRMS(ESI)理论计算C16H11F2N2[MH+]:269.0885。实际测定:269.0886。理论分析计算C16H10F2N2:C,71.64;H,3.76;N,10.44。实际测定:C,71.48;H,3.83;N,10.39。
5-((2,6-二氟苯基)乙炔基)-1H-吡咯并[2,3-b]吡啶(5l).收率45%;用1:2乙酸乙酯-己烷的柱色谱法;mp 192-194℃。1H NMR(400MHz,DMSO-d6)δ11.99(s,1H),8.41(d,J=2Hz,1H),8.22(d,J=2Hz,1H),7.59(t,J=3Hz,1H),7.57-7.47(m,1H),7.26(t,J=8Hz,2H),6.52(dd,J=1.8,3.5Hz,1H)。13C NMR(101MHz,DMSO-d6)δ161.95(dd,J=5.2,251.2Hz,2C),147.80,145.04,131.21,131.02(t,J=10.3Hz),127.83,119.20,111.76(dd,J=5,19Hz,2C),109.53,101.29(t,J=19.9Hz),100.42,98.22(t,J=3Hz),75.88。HRMS(ESI)理论计算C15H9F2N2[MH+]:255.0728。实际测定:255.0710。理论分析计算C15H8F2N2:C,70.86;H,3.17;N,11.02。实际测定:C,70.57;H,3.17;N,10.88。
2-((2,6-二氟苯基)乙炔基)喹啉(5m).收率83%;用1:5乙酸乙酯-己烷的柱色谱法;mp127-129℃。1H NMR(400MHz,DMSO-d6)δ8.48(d,J=8.5Hz,1H),8.09-8.02(m,2H),7.89-7.82(m,1H),7.76(d,J=8.4Hz,1H),7.72-7.66(m,1H),7.66-7.58(m,1H),7.32(t,J=8.1Hz,2H)。13C NMR(101MHz,DMSO-d6)δ162.44(dd,J=5,252.8Hz,2C),147.66,141.73,137.07,132.57(t,J=10.2Hz),130.62,128.75,128.05,127.82,127.15,124.25,112.16(dd,J=4.6,19Hz,2C),99.97(t,J=19.7Hz),98.51(t,J=3Hz),75.62。HRMS(ESI)理论计算C17H10F2N[MH+]:266.0776。实际测定:266.0756。理论分析计算C17H9F2N:C,76.98;H,3.42;N,5.28。实际测定:C,76.73;H,3.38;N,5.17。
3-((2,6-二氟苯基)乙炔基)喹啉(5n).收率64%;用1:10乙酸乙酯-己烷的制备层色谱法(Rf=0.42);mp 115-117℃。1H NMR(400MHz,DMSO-d6)δ9(d,J=2.1Hz,1H),8.72(d,J=2.2Hz,1H),8.06(d,J=8.4Hz,2H),7.85(t,J=7.6Hz,1H),7.69(t,J=7.6Hz,1H),7.64-7.52(m,1H),7.30(t,J=8.1Hz,2H)。13C NMR(101MHz,DMSO-d6)δ162.12(dd,J=5,252.2Hz,2C),151.13,146.64,139.13,132.02(t,J=10.2Hz),131.04,128.87,128.29,127.7,126.73,115.41,112.06(dd,J=5,18.7Hz,2C),100.46(t,J=19.7Hz),96.21(t,J=3.1Hz),78.9。HRMS(ESI)理论计算C17H10F2N[MH+]:266.0776。实际测定:266.0757。理论分析计算C17H9F2N:C,76.98;H,3.42;N,5.28。实际测定:C,76.68;H,3.50;N,5.11。
4-((2,6-二氟苯基)乙炔基)喹啉(5o).收率68%;用1:5乙酸乙酯-己烷的柱色谱法;mp 101-102℃。1H NMR(400MHz,DMSO-d6)δ8.97(d,J=4.4Hz,1H),8.29(d,J=8.1Hz,1H),8.12(d,J=8.3Hz,1H),7.95-7.84(m,1H),7.83-7.75(m,2H),7.70-7.58(m,1H),7.34(t,J=8.1Hz,2H)。13C NMR(101MHz,DMSO-d6)δ162.22(dd,J=4.9,252.9Hz,2C),150.26,147.50,132.8(t,J=10.2Hz),130.44,129.78,128.15,127.1,126.35,124.97,123.86,112.21(dd,J=5.3,19Hz,2C),100.06(t,J=19.8Hz),94.17(t,J=3Hz),84.92。HRMS(ESI)理论计算C17H10F2N[MH+]:266.0776。实际测定:266.0757。理论分析计算C17H9F2N:C,76.98;H,3.42;N,5.28。实际测定:C,77.21;H,3.43;N,5.24。
2-氯-3-((2,6-二氟苯基)乙炔基)喹啉(5p).收率53%;用1:5乙酸乙酯-己烷的柱色谱法;mp 137-138℃。1H NMR(400MHz,DMSO-d6)δ8.89(s,1H),8.1(d,J=8.2Hz,1H),8(d,J=8.5Hz,1H),7.93-7.84(m,1H),7.77-7.69(m,1H),7.68-7.56(m,1H),7.31(t,J=8.1Hz,2H)。13C NMR(101MHz,DMSO-d6)δ162.2(dd,J=5,252.8Hz,2C),148.86,146.09,143,132.47(t,J=10.1Hz),132.3,128.28,128.16,127.84,126.14,115.72,112.17(dd,J=4.5,19Hz,2C),100.22(t,J=19.7Hz),94.07(t,J=2.9Hz),82.23。HRMS(ESI)理论计算C17H9ClF2N[MH+]:300.0386。实际测定:300.0368。理论分析计算C17H8ClF2N:C,68.13;H,2.69;N,4.67。实际测定:C,68.16;H,2.73;N,4.38。
4-氯-3-((2,6-二氟苯基)乙炔基)喹啉(5q).收率40%;从甲醇重结晶;mp140-142℃。1H NMR(400MHz,DMSO-d6)δ9.03(s,1H),8.27(d,J=8.4Hz,1H),8.14(d,J=8.4Hz,1H),7.94(t,J=7.7Hz,1H),7.84(t,J=7.7Hz,1H),7.7-7.56(m,1H),7.32(t,J=8.2Hz,2H)。13CNMR(101MHz,DMSO-d6)δ162.11(dd,J=4.9,253.1Hz,2C),151.25,147.27,143,132.62(t,J=10.2Hz),131.84,129.65,129.22,124.83,124.17,115.77,112.16(dd,J=4.6,19Hz,2C),100.15(t,J=19.7Hz),93.43(t,J=3Hz),84.18。HRMS(ESI)理论计算C17H9ClF2N[MH+]:300.0386。实际测定:300.0366。理论分析计算C17H8ClF2N:C,68.13;H,2.69;N,4.67。实际测定:C,67.84;H,2.82;N,4.53。
3-((2,6-二氟苯基)乙炔基)喹啉-6-胺(5r).收率67%;用2:1乙酸乙酯-己烷的柱色谱法;mp184-185℃。1H NMR(400MHz,DMSO-d6)δ8.54(d,J=2.1Hz,1H),8.26(d,J=2.1Hz,1H),7.73(d,J=9Hz,1H),7.63-7.51(m,1H),7.29(t,J=8Hz,2H),7.22(dd,J=2.4,9Hz,1H),6.83(d,J=2.5Hz,1H),5.82(s,2H)。13C NMR(101MHz,DMSO-d6)δ162.10(dd,J=5.1,251.9Hz,2C),148.05,145.57,140.98,135.88,131.76(t,J=10.2Hz),129.62,128.76,123,115.13,112.07(dd,J=5,18.7Hz,2C),104.41,100.8(t,J=19.7Hz),97.1(t,J=3.1Hz),78.02。HRMS(ESI)理论计算C17H11F2N2[MH+]:281.0885。实际测定:281.0864。理论分析计算C17H10F2N2:C,72.85;H,3.60;N,10.00。实际测定:C,72.57;H,3.64;N,9.84。
3-((2,6-二氟苯基)乙炔基)-7-氟喹啉(5s).收率87%;用1:5乙酸乙酯-己烷的柱色谱法;mp 142-143℃。1H NMR(400MHz,DMSO-d6)δ9.03(d,J=2Hz,1H),8.77(d,J=2.1Hz,1H),8.17(dd,J=6.3,9.1Hz,1H),7.83(dd,J=2.5,10.3Hz,1H),7.66(td,J=2.6,8.9Hz,1H),7.61-7.54(m,1H),7.3(t,J=8.1Hz,2H)。13C NMR(101MHz,DMSO-d6)δ163.16(d,J=250.1Hz),162.12(dd,J=5.1,252.3Hz,2C),152.29,147.61(d,J=13Hz),139.24(d,J=1.3Hz),132.07(t,J=10.2Hz),131.14(d,J=10.3Hz),124.09,118.13(d,J=25.5Hz),114.95(d,J=2.7Hz),112.58(d,J=20.6Hz),112.10(dd,J=5.3,18.9Hz,2C),100.4(t,J=19.7Hz),95.94(t,J=2.9Hz),78.94。HRMS(ESI)理论计算C17H9F3N[MH+]:284.0682。实际测定:284.0661。理论分析计算C17H8F3N:C,72.09;H,2.85;N,4.95。实际测定:C,71.83;H,2.94;N,4.70。
3-((2,6-二氟苯基)乙炔基)-8-氟喹啉(5t).收率79%;从甲醇重结晶;mp136-137℃。1H NMR(400MHz,DMSO-d6)δ9.05(d,J=2Hz,1H),8.8(s,1H),7.97-7.84(m,1H),7.75-7.65(m,2H),7.64-7.56(m,1H),7.31(t,J=8.1Hz,2H)。13C NMR(101MHz,DMSO-d6)δ162.15(dd,J=5,252.4Hz,2C),157.08(d,J=255.6Hz),151.38(d,J=1.5Hz),139.04(d,J=2.9Hz),136.37(d,J=12Hz),132.25(t,J=10.2Hz),128.44(d,J=2Hz),127.91(d,J=8Hz),124.26(d,J=4.6Hz),116.55,115.22(d,J=18.4Hz),112.11(dd,J=5,18.6Hz,2C),100.27(t,J=19.7Hz),95.71(t,J=3Hz),79.59。HRMS(ESI)理论计算C17H9F3N[MH+]:284.0682。实际测定:284.0661。理论分析计算C17H8F3N:C,72.09;H,2.85;N,4.95。实际测定:C,71.79;H,2.92;N,4.95。
7-氯-4-((2,6-二氟苯基)乙炔基)喹啉(5u).收率80%;在1:150甲醇-二氯甲烷中的柱色谱法;mp 130-132℃。1H NMR(400MHz,DMSO-d6)δ8.99(d,J=4.4Hz,1H),8.25(d,J=8.9Hz,1H),8.17(d,J=2.1Hz,1H),7.83(dd,J=2.1,8.9Hz,1H),7.80(d,J=4.5Hz,1H),7.7-7.59(m,1H),7.34(t,J=8.2Hz,2H)。13C NMR(101MHz,DMSO-d6)δ162.24(dd,J=4.9,253.1Hz,2C),151.62,147.83,135.06,133.04(t,J=10.3Hz),128.78,128.42,127.32,127.01,125.05,124.22,112.24(dd,J=4.5,19Hz,2C),99.89(t,J=19.6Hz),93.66(t,J=3Hz),85.43。HRMS(ESI)理论计算C17H9ClF2N[MH+]:300.0386。实际测定:300.0366。理论分析计算C17H8ClF2N:C,68.13;H,2.69;N,4.67。实际测定:C,67.96;H,2.68;N,4.68。
5-((2,6-二氟苯基)乙炔基)喹啉(5v).收率68%;用1:10乙酸乙酯-己烷的制备层色谱法(Rf=0.45);mp 98-100℃。1H NMR(400MHz,DMSO-d6)δ9.04-9(m,1H),8.64(d,J=8.2Hz,1H),8.15(dd,J=2.5,8.5Hz,1H),7.94(dd,J=2.8,7.2Hz,1H),7.9-7.78(m,1H),7.78-7.69(m,1H),7.66-7.52(m,1H),7.40-7.23(m,2H)。13C NMR(101MHz,DMSO-d6)δ162.06(dd,J=5.1,251.9Hz,2C),151.47,147.34,133.17,131.9(t,J=10.2Hz),131.13,131.06,129.35,127.62,122.86,119.2,112.06(dd,J=5.3,18.3Hz,2C),100.56(t),95.63(t,J=3.1Hz),81.48。HRMS(ESI)理论计算C17H10F2N[MH+]:266.0776。实际测定:266.0758。理论分析计算C17H9F2N:C,76.98;H,3.42;N,5.28。实际测定:C,76.80;H,3.47;N,5.15。
6-((2,6-二氟苯基)乙炔基)喹啉(5w).收率80%;用1:2乙酸乙酯-己烷的柱色谱法;mp 91-93℃。1H NMR(400MHz,DMSO-d6)δ8.96(dd,J=1.8,4.2Hz,1H),8.44(d,J=8.1Hz,1H),8.33(d,J=1.9Hz,1H),8.07(d,J=8.7Hz,1H),7.86(dd,J=1.9,8.7Hz,1H),7.61(dd,J=4.2,8.3Hz,1H),7.59-7.52(m,1H),7.29(t,J=8.1Hz,2H)。13C NMR(101MHz,DMSO-d6)δ162.12(dd,J=5.1,251.9Hz,2C),151.86,147.35,136.13,132.05,131.74(t,J=10.2Hz),131.38,129.7,127.75,122.44,119.23,112.01(dd,J=4.9,18.7Hz,2C),100.67(t,J=19.7Hz),98.47(t,J=3Hz),76.91。HRMS(ESI)理论计算C17H10F2N[MH+]:266.0776。实际测定:266.0758。理论分析计算C17H9F2N:C,76.98;H,3.42;N,5.28。实际测定:C,76.97;H,3.33;N,5.29。
7-((2,6-二氟苯基)乙炔基)喹啉(5x).收率74%;用1:10乙酸乙酯-己烷的制备层色谱法(Rf=0.49);mp 123-125℃.1H NMR(400MHz,DMSO-d6)δ8.98(dd,J=1.7,4.2Hz,1H),8.43(d,J=8.2Hz,1H),8.21(d,J=1.1Hz,1H),8.07(d,J=8.4Hz,1H),7.73(dd,J=1.6,8.4Hz,1H),7.66-7.5(m,2H),7.29(t,J=8.1Hz,2H)。13C NMR(101MHz,DMSO-d6)δ162.13(dd,J=5,252Hz,2C),151.81,147.12,136.01,132.15,131.86(t,J=10.2Hz),129.08,128.46,128.24,122.56,122.21,112.7-111.37(dd,J=5,18.6Hz,2C),100.62(t,J=19.8Hz),98.35(t,J=3.1Hz),77.65。HRMS(ESI)理论计算C17H10F2N[MH+]:266.0776。实际测定:266.0757。理论分析计算C17H9F2N:C,76.98;H,3.42;N,5.28。实际测定:C,77.15;H,3.28;N,5.31。
8-((2,6-二氟苯基)乙炔基)喹啉(5y).收率62%;用1:5乙酸乙酯-己烷的柱色谱法;mp 108-110℃。1H NMR(400MHz,DMSO-d6)δ9.04(dd,J=1.8,4.2Hz,1H),8.47(dd,J=1.8,8.3Hz,1H),8.11(d,J=8.2Hz,1H),8.08(dd,J=1.4,7.2Hz,1H),7.7-7.62(m,2H),7.6-7.5(m,1H),7.28(t,J=8Hz,2H)。13C NMR(101MHz,DMSO-d6)δ162.07(dd,J=5.2,251.6Hz,2C),151.47,147.17,136.71,134.39,131.37(t,J=10.2Hz),130,128.02,126.3,122.36,121.25,111.94(dd,J=5.3,19Hz,2C),101.33(t,J=19.6Hz),97.3(t,J=3Hz),80.76。HRMS(ESI)理论计算C17H10F2N[MH+]:266.0776。实际测定:266.0757。理论分析计算C17H9F2N:C,76.98;H,3.42;N,5.28。实际测定:C,76.68;H,3.30;N,5.29。
2-氯-6-((2,6-二氟苯基)乙炔基)喹啉(5z).收率67%;用1:5乙酸乙酯-己烷的柱色谱法;mp 137-138℃。1H NMR(400MHz,DMSO-d6)δ8.51(d,J=8.7Hz,1H),8.39(s,1H),8(d,J=8.7Hz,1H),7.92(dd,J=8.7,1.6Hz,1H),7.69(d,J=8.6Hz,1H),7.63-7.53(m,1H),7.29(t,J=8.1Hz,2H)。13C NMR(100MHz,DMSO-d6)δ162.14(dd,J=252,5.1Hz,2C),151.17,146.89,140.01,132.81,131.97,131.93(t,J=10.2Hz),128.64,126.69,123.53,119.89,112.06,(dd,J=5.3,19Hz,2C),100.54(t,J=19.8Hz),98.05(t,J=3Hz).77.38。HRMS(ESI)理论计算C17H9ClF2N[MH+]:300.0386。实际测定:300.0366。理论分析计算C17H8ClF2N:C,68.13;H,2.69;N,4.67。实际测定:C,67.93;H,2.70;N,4.49。
4-氯-6-((2,6-二氟苯基)乙炔基)喹啉(5aa).收率64%;用1:5乙酸乙酯-己烷的制备层色谱法(Rf=0.33)并从己烷中重结晶;mp 120-122℃。1H NMR(700MHz,DMSO-d6)δ8.89(d,J=4.7Hz,1H),8.33(d,J=1.8Hz,1H),8.14(d,J=8.6Hz,1H),7.96(dd,J=1.8,8.6Hz,1H),7.84(d,J=4.7Hz,1H),7.67-7.5(m,1H),7.29(t,J=8Hz,2H)。13C NMR(176MHz,DMSO-d6)δ162.14(dd,J=4.9,252.3Hz,2C),151.75,148.13,140.97,132.55,132(t,J=10.1Hz),130.46,127.06,125.49,122.61,120.88,112.00(dd,J=3.8,20.1Hz,2C),100.41(t,J=19.7Hz),97.85(t,J=3Hz),77.94。HRMS(ESI)理论计算C17H9ClF2N[MH+]:300.0386。实际测定:300.0389。理论分析计算C17H8ClF2N:C,68.13;H,2.69;N,4.67。实际测定:C,67.85;H,2.79;N,4.53。
4-氯-7-((2,6-二氟苯基)乙炔基)喹啉(5bb).收率63%;用1:5乙酸乙酯-己烷的柱色谱法并从乙腈中重结晶;mp 148-150℃。1H NMR(400MHz,DMSO-d6)δ8.92(d,J=4.7Hz,1H),8.28(d,J=1.7Hz,1H),8.25(d,J=8.7Hz,1H),7.88(dd,J=1.7,8.6Hz,1H),7.84(d,J=4.7Hz,1H),7.64-7.52(m,1H),7.30(t,J=8.1Hz,2H)。13C NMR(101MHz,DMSO-d6)δ162.16(dd,J=5,252.3Hz,2C),151.83,148.07,141.2,132.55,132.16(t,J=10.1Hz),130.06,125.83,124.76,123.5,122.66,112.08(dd,J=5.3,19Hz,2C),100.4(t,J=19.7Hz),97.62(t,J=3Hz),78.63。HRMS(ESI)理论计算C17H9ClF2N[MH+]:300.0386。实际测定:300.0365。理论分析计算C17H8ClF2N:C,68.13;H,2.69;N,4.67。实际测定:C,68.41;H,2.97;N,4.42。
6-((2,6-二氟苯基)乙炔基)喹啉-4-胺(5cc).收率93%;用1:10甲醇-二氯甲烷的柱色谱法;mp 220-222℃。1H NMR(700MHz,DMSO-d6)δ8.54(s,1H),8.35(brs,1H),7.79(d,J=8.6Hz,1H),7.73(dd,J=1.7,8.6Hz,1H),7.61-7.51(m,1H),7.29(t,J=8Hz,2H),7.27(s,2H),6.62(d,J=5.3Hz,1H)。13C NMR(176MHz,DMSO-d6)δ162.07(dd,J=5,251.6Hz,2C),152.28,150.46,147.61,131.44,131.41(t,J=10.1Hz),128.67,126.82,118.06,116.27,111.98(dd,J=5,18.6Hz,2C),103.1,100.91(t,J=19.8Hz),99.23(t,J=3Hz),76.01。HRMS(ESI)理论计算C17H11F2N2[MH+]:281.0885。实际测定:281.0887。理论分析计算C17H10F2N2:C,72.85;H,3.60;N,10.00。实际测定:C,72.84;H,3.52;N,10.06。
7-((2,6-二氟苯基)乙炔基)喹啉-4-胺(5dd).收率61%;用乙酸乙酯的柱色谱法;mp 219-221℃。1H NMR(700MHz,DMSO-d6)δ8.37(brs,1H),8.23(d,J=8.6Hz,1H),7.94(s,1H),7.6-7.54(m,1H),7.51(dd,J=1.5,8.6Hz,1H),7.29(t,J=8Hz,2H),6.93(s,2H),6.6(d,J=5.1Hz,1H)。13C NMR(176MHz,DMSO-d6)δ162.1(dd,J=5.0,251.8Hz,2C),151.45,151.4,148.33,132.32,131.63(t,J=10.1Hz),125.22,123.49,121.57,118.88,111.98(dd,J=3.7,20.3Hz,2C),103.21,100.78(t,J=19.7Hz),98.75(t,J=2.9Hz),76.85。HRMS(ESI)理论计算C17H11F2N2[MH+]:281.0885。实际测定:281.0885。理论分析计算C17H10F2N2:C,72.85;H,3.60;N,10.00。实际测定:C,72.57;H,3.73;N,9.96。
通过亲核芳族取代合成N,N-二甲基氨基取代的喹啉的一般程序。
130mg(0.43mmol)合适的氯取代的喹啉和2.2mL(4.3mmol,10当量)的含2M甲胺或二甲胺的THF溶液混合后在130℃下在压力管中搅拌2-3小时。将该混合物倒入水中,用二氯甲烷萃取,用无水硫酸镁干燥,浓缩并通过色谱法纯化,如针对单个化合物所述。
6-((2,6-二氟苯基)乙炔基)-N,N-二甲基喹啉-2-胺(5ee).收率67%;用1:5乙酸乙酯-己烷的制备层色谱法(Rf=0.53)并从abs.乙醇中重结晶;mp142-144℃。1H NMR(700MHz,DMSO-d6)δ8.05(d,J=9.1Hz,1H),7.98(d,J=1.9Hz,1H),7.6(dd,J=2.0,8.6Hz,1H),7.54(d,J=8.6Hz,1H),7.53-7.48(m,1H),7.29-7.23(m,2H),7.14(d,J=9.2Hz,1H),3.19(s,6H)。13C NMR(176MHz,DMSO-d6)δ161.97(dd,J=5.2,251.1Hz,2C),157.82,147.85,136.93,131.54,131.42,130.93(t,J=10Hz),126.25,121.85,113.31,111.88(dd,J=3.9,20.2Hz,2C),110.48,101.25(t,J=19.8Hz),99.78(t,J=2.9Hz),75.07,37.61(2C)。HRMS(ESI)理论计算C19H15F2N2[MH+]:309.1198。实际测定:309.1198。理论分析计算C19H14F2N2:C,74.01;H,4.58;N,9.09。实际测定:C,74.04;H,4.59;N,9.09。
6-((2,6-二氟苯基)乙炔基)-N,N-二甲基喹啉-4-胺(5ff).收率64%;用1:1乙酸乙酯-己烷的制备层色谱法(Rf=0.41);mp 118-120℃.1H NMR(700MHz,DMSO-d6)δ8.62(d,J=5.2Hz,1H),8.22(d,J=1.9Hz,1H),7.94(d,J=8.6Hz,1H),7.76(dd,J=1.9,8.6Hz,1H),7.55(m,1H),7.27(t,J=8Hz,2H),6.91(d,J=5.2Hz,1H),3.02(s,6H)。13C NMR(176MHz,DMSO-d6)δ162.08(dd,J=5.1,251.7Hz,2C),156.56,151.52,149.18,131.51(t,J=10.1Hz),130.73,130.23,128.42,121.95,117.04,111.95(dd,J=3.8,20.2Hz,2C),108.06,100.84(t,J=19.7Hz),99.05(t,J=3Hz),76.28,43.54(2C)。HRMS(ESI)理论计算C19H15F2N2[MH+]:309.1198。实际测定:309.1201。理论分析计算C19H14F2N2:C,74.01;H,4.58;N,9.09。实际测定:C,73.75;H,4.66;N,9.11。
1-((2,6-二氟苯基)乙炔基)异喹啉(5gg).收率72%;用1:5乙酸乙酯-己烷的柱色谱法;mp 120-122℃.1H NMR(400MHz,DMSO-d6)δ8.6(d,J=5.6Hz,1H),8.45-8.37(m,1H),8.13-8.05(m,1H),7.97(d,J=5.6Hz,1H),7.92-7.81(m,2H),7.74-7.57(m,1H),7.35(t,J=8.1Hz,2H)。13C NMR(101MHz,DMSO-d6)δ162.44(dd,J=5,252.7Hz,2C),143.08,142.14,135.38,132.71(t,J=10.2Hz),131.22,129.13,128.6,127.47,125.45,121.74,112.21(dd,J=5.4,18.3Hz,2C),100.04(t,J=19.7Hz),96.00(t,J=3.1Hz),80。HRMS(ESI)理论计算C17H10F2N[MH+]:266.0776。实际测定:266.0758。理论分析计算C17H9F2N:C,76.98;H,3.42;N,5.28。实际测定:C,76.92;H,3.50;N,5.20。
4-((2,6-二氟苯基)乙炔基)异喹啉(5hh).收率73%;用1:5乙酸乙酯-己烷的柱色谱法;mp102-104℃。1H NMR(400MHz,DMSO-d6)δ9.41(s,1H),8.79(s,1H),8.25(t,J=9.1Hz,2H),7.99(t,J=7.6Hz,1H),7.82(t,J=7.6Hz,1H),7.68-7.53(m,1H),7.32(t,J=8.1Hz,2H)。13C NMR(101MHz,DMSO-d6)δ162.04(dd,J=5,252.1Hz,2C),153.34,146.2,134.33,132.32,132.06(t,J=10.2Hz),128.63,128.57,127.34,123.75,113.84,112.09(dd,J=4.9,18.6Hz,2C),100.58(t,J=19.6Hz),94.01(t,J=3Hz),83.24。HRMS(ESI)理论计算C17H10F2N[MH+]:266.0776。实际测定:266.0758。理论分析计算C17H9F2N:C,76.98;H,3.42;N,5.28。实际测定:C,76.68;H,3.49;N,5.10。
5-((2,6-二氟苯基)乙炔基)异喹啉(5ii).收率85%;用1:1乙酸乙酯-己烷的柱色谱法;mp115-117℃。1H NMR(400MHz,DMSO-d6)δ9.44(s,1H),8.7(d,J=5.8Hz,1H),8.27(d,J=8.3Hz,1H),8.11(dd,J=1.1,7.2Hz,1H),8.08(d,J=5.9Hz,1H),7.81-7.72(m,1H),7.66-7.55(m,1H),7.33(t,J=8.1Hz,2H)。13C NMR(101MHz,DMSO-d6)δ162.06(dd,J=5.1,252Hz,2C),153.14,144.54,134.88,134.71,131.97(t,J=10.1Hz),129.62,127.91,127.36,117.86,117.53,112.1(dd,J=5.3,19Hz,2C),100.63(t,J=19.6Hz),95.41(t,J=3Hz),81.86。HRMS(ESI)理论计算C17H10F2N[MH+]:266.0776。实际测定:266.0756。理论分析计算C17H9F2N:C,76.98;H,3.42;N,5.28。实际测定:C,76.75;H,3.47;N,5.23。
6-((2,6-二氟苯基)乙炔基)异喹啉(5jj).收率75%,用1:1乙酸乙酯-己烷的柱色谱法;mp 97-99℃。1H NMR(400MHz,DMSO-d6)δ9.38(s,1H),8.58(d,J=6.1Hz,1H),8.3(s,1H),8.2(d,J=8.5Hz,1H),7.9(d,J=5.7Hz,1H),7.79(dd,J=1.6,8.5Hz,1H),7.68-7.5(m,1H),7.3(t,J=8.1Hz,2H)。13C NMR(101MHz,DMSO-d6)δ162.18(dd,J=5,252.1Hz,2C),152.35,143.91,134.84,132.1(t,J=10.2Hz),130.25,129.29,128.44,123.12,120.19,112.11(dd,J=5.0,19Hz,2C),100.37(t,J=19.7Hz),98.29(t,J=3.2Hz),78.06。HRMS(ESI)理论计算C17H10F2N[MH+]:266.0776。实际测定:266.0757。理论分析计算C17H9F2N:C,76.98;H,3.42;N,5.28。实际测定:C,77.16;H,3.39;N,5.21。
1-氯-4-((2,6-二氟苯基)乙炔基)异喹啉(5kk).收率48%;用1:5乙酸乙酯-己烷的制备层色谱法(Rf=0.62)并从abs.乙醇重结晶;mp 145-146℃。1H NMR(700MHz,DMSO-d6)δ8.63(s,1H),8.39(d,J=8.2Hz,1H),8.3(d,J=8.3Hz,1H),8.1(ddd,J=1.2,6.9,8.2Hz,1H),7.95(ddd,J=1.1,6.9,8.3Hz,1H),7.66-7.58(m,1H),7.33(t,J=8.1Hz,2H)。13C NMR(176MHz,DMSO-d6)δ162.06(dd,J=4.9,252.5Hz,2C),151.11,144.73,136.29,133.31,132.36(t,J=10.1Hz),130.35,126.5,125.37,124.82,114.66,112.13(dd,J=3.7,20.1Hz,2C),100.31(t,J=19.7Hz),93(t,J=3.0Hz),84.26。HRMS(ESI)理论计算C17H9ClF2N[MH+]:300.0386。实际测定:300.0388。理论分析计算C17H8ClF2N:C,68.13;H,2.69;N,4.67。实际测定:C,68.06;H,2.78;N,4.61。
1-((2,6-二氟苯基)乙炔基)-7-氟异喹啉(5ll).收率56%;用1:200甲醇-二氯甲烷的柱色谱法;mp 177-178℃。1H NMR(400MHz,DMSO-d6)δ8.61(d,J=5.5Hz,1H),8.23(dd,J=5.5,9.1Hz,1H),8.07-7.96(m,2H),7.83(td,J=2.6,8.9Hz,1H),7.71-7.57(m,1H),7.35(t,J=8.2Hz,2H)。13C NMR(101MHz,DMSO-d6)δ162.43(dd,J=5,252.8Hz,2C),161.17(d,J=249.3Hz),142.77(d,J=2.4Hz),141.58(d,J=6Hz),132.93,132.79(d,J=8.6Hz),131.15(d,J=8.9Hz),129.49(d,J=8.8Hz),121.79(d,J=25.6Hz),121.56(d,J=1.6Hz),112.23(dd,J=5,18.7Hz,2C),108.72(d,J=22.2Hz),99.91(t,J=19.7Hz),95.49(t,J=2.7Hz),80.54。HRMS(ESI)理论计算C17H9F3N[MH+]:284.0682。实际测定:284.0662。理论分析计算C17H8F3N:C,72.09;H,2.85;N,4.95。实际测定:C,71.98;H,2.69;N,4.91。
4-((2,6-二氟苯基)乙炔基)异喹啉-1-胺(5mm).收率71%;用1:10甲醇-二氯甲烷的柱色谱法并从甲醇重结晶;mp200-201℃。1H NMR(400MHz,DMSO-d6)δ8.31(d,J=8.3Hz,1H),8.17(s,1H),8.04(d,J=8.2Hz,1H),7.82(t,J=7.6Hz,1H),7.59(t,J=7.6Hz,1H),7.55-7.43(m,3H),7.26(t,J=7.9Hz,2H)。13C NMR(101MHz,DMSO-d6)δ162.04(dd,J=5.4,250.5Hz,2C),158.49,147.85,136.25,131.71,130.77(t,J=10Hz),126.86,125,124.33,116.64,111.85(dd,J=5.4,18.3Hz,2C),102.27,102.23(t,J=19.9Hz),97.26(t,J=2.9Hz),80.27。HRMS(ESI)理论计算C17H11F2N2[MH+]:281.0885。实际测定:281.0866。理论分析计算C17H10F2N2:C,72.85;H,3.60;N,10.00。实际测定:C,73.13;H,3.69;N,9.93。
4-((2,6-二氟苯基)乙炔基)-N,N-二甲基异喹啉-1-胺(5nn).收率75%;用1:5乙酸乙酯-己烷的制备层色谱法(Rf=0.47);mp 122-124℃。1H NMR(700MHz,DMSO-d6)δ8.31(s,1H),8.23-8.16(m,1H),8.13(dd,J=1.2,8.3Hz,1H),7.84(ddd,J=1.2,6.9,8.2Hz,1H),7.62(ddd,J=1.3,6.8,8.3Hz,1H),7.56-7.48(m,1H),7.28(t,J=7.9Hz,2H),3.19(s,6H)。13C NMR(176MHz,DMSO-d6)δ161.72(dd,J=5.3,250.9Hz,2C),160.63,145.03,137.01,130.96,130.82(t,J=10.1Hz),126.80,126.2,124.21,118.3,111.91(dd,J=3.8,20.1Hz,2C),105.07,101.45(t,J=19.8Hz),95.96(t,J=2.9Hz),81.00,42.45(2C)。HRMS(ESI)理论计算C19H15F2N2[MH+]:309.1198。实际测定:309.1200。理论分析计算C19H14F2N2:C,74.01;H,4.58;N,9.09。实际测定:C,73.75;H,4.60;N,9.00。
4-((2,6-二氟苯基)乙炔基)-N-甲基异喹啉-1-胺(5oo).收率60%,Rf=0.48(1:2乙酸乙酯-己烷),mp 118-120℃。1H NMR(400MHz,DMSO-d6)δ8.28(d,J=8.6Hz,1H),8.25(s,1H),8.08(t,J=4.5Hz,1H),8.05(d,J=9.1Hz,1H),7.81(t,J=7.5Hz,1H),7.61(t,J=7.5Hz,1H),7.55-7.44(m,1H),7.26(t,J=7.9Hz,2H),3.03(d,J=4.5Hz,3H)。13C NMR(101MHz,DMSO-d6)δ161.61(dd,J=5.4,250.4Hz,2C),156.29,147.12,135.26,130.99,130.33(t,J=10.1Hz),126.6,124.05,123.44,117.01,112.01(dd,J=3.8,20.1Hz,2C),101.78(t,J=19.9Hz),101.45,96.88(t,J=2.9Hz),79.90,28.29。HRMS(ESI)理论计算C18H13F2N2[MH+]:295.1041。实际测定:295.1035。理论分析计算C18H12F2N2:C,73.46;H,4.11;N,9.52。实际测定:C,73.49;H,4.23,N,9.61。
4-((2,6-二氟苯基)乙炔基)-1-(4-甲基哌嗪-1-基)异喹啉(5pp).收率79%,Rf=0.42(1:10甲醇-二氯甲烷),mp70-72℃。1H NMR(400MHz,DMSO-d6)δ8.38(s,1H),8.16(d,J=8.1Hz,1H),8.11(d,J=8.4Hz,1H),7.88(ddd,J=1.2,6.9,8.2Hz,1H),7.68(ddd,J=1.3,6.9,8.3Hz,1H),7.61-7.5(m,1H),7.29(t,J=8Hz,2H),3.47(t,J=5Hz,4H),2.57(t,J=4.7Hz,4H),2.27(s,3H)。13C NMR(101MHz,DMSO-d6)δ161.82(dd,J=5.3,251.1Hz,2C),160.77,144.84,136.70,131.31,131.15(t,J=9.2Hz),127.19,126.14,124.54,119.27,112.12(dd,J=3.7,20.1Hz,2C),107.32,101.20(t,J=19.7Hz),95.34(t,J=3Hz),81.52,54.56(2C),50.65(2C),45.78。HRMS(ESI)理论计算C22H20F2N3[MH+]:364.1620。实际测定:364.1614。理论分析计算C22H19F2N3:C,72.71;H,5.27;N,11.56。实际测定:C,72.91;H,5.12,N,11.67。
8-((2,6-二氟苯基)乙炔基)-N,N-二甲基-1,6-萘啶-5-胺(5qq).收率76%,Rf=0.29(1:2乙酸乙酯-己烷),mp 149-150℃。1H NMR(400MHz,DMSO-d6)δ9.04(dd,J=1.7,4.2Hz,1H),8.59(dd,J=1.7,8.5Hz,1H),8.45(s,1H),7.57(dd,J=4.2,8.5Hz,1H),7.53-7.46(m,1H),7.25(t,J=8Hz,2H),3.25(s,6H)。13C NMR(101MHz,DMSO-d6)δ161.9(dd,J=5.3,250.9Hz,2C),160.35,153.88,152.18,148.92,135.3,130.67(t,J=10.1Hz),120.82,113.48,111.84(dd,J=3.8,20.1Hz,2C),106.58,101.86(t,J=19.8Hz),96.37(t,J=3.0Hz),79.73,42.31(2C)。HRMS(ESI)理论计算C18H14F2N3[MH+]:310.1150。实际测定:310.1147。理论分析计算C18H13F2N3:C,69.89;H,4.24;N,13.58。实际测定:C,70.01;H,4.44,N,13.53。
7-((2,6-二氟苯基)乙炔基)喹唑啉(5rr).收率68%;从乙腈重结晶;mp166-168℃。1H NMR(400MHz,DMSO-d6)δ9.68(s,1H),9.37(s,1H),8.25(d,J=8.4Hz,1H),8.2(s,1H),7.89(dd,J=1.6,8.4Hz,1H),7.69-7.53(m,1H),7.31(t,J=8.1Hz,2H)。13C NMR(101MHz,DMSO-d6)δ162.19(dd,J=4.9,252.6Hz,2C),160.85,156.02,148.92,132.46(t,J=10.2Hz),130.75,130.11,128.79,127.1,124.50,112.14(dd,J=5,18.6Hz,2C),100.21(t,J=19.7Hz),97.51(t,J=3Hz),79.73。HRMS(ESI)理论计算C16H9F2N2[MH+]:267.0728。实际测定:267.0710。理论分析计算C16H8F2N2:C,72.18;H,3.03;N,10.52。实际测定:C,71.97;H,3.22;N,10.29。
3,5-二氟-4-(苯乙炔基)吡啶(7a).收率88%;用1:20乙酸乙酯-己烷(Rf=0.48)的制备层色谱法;mp 52-54℃。1H NMR(400MHz,DMSO-d6)δ8.67(s,2H),7.69-7.62(m,2H),7.58-7.47(m,3H)。13C NMR(101MHz,DMSO-d6)δ157.60(d,J=264.1Hz,2C),134.52(dd,J=21.8,4.6Hz,2C),131.87(2C),130.58,129.09(2C),120.20,108.59(t,J=16.5Hz),103.10(t,J=2.9Hz),73.82。HRMS(ESI)理论计算C13H8F2N[MH+]:216.0619。实际测定:216.0619。理论分析计算C13H7F2N:C,72.56;H,3.28;N,6.51。实际测定:C,72.78;H,3.38,N,6.58。
4-((3,5-二氟吡啶-4-基)乙炔基)苯胺(7b).收率69%;用1:5乙酸乙酯-己烷的制备层色谱法(Rf=0.3);mp 156-158℃。1H NMR(400MHz,DMSO-d6)δ8.58(s,2H),7.28(d,J=8.4Hz,2H),6.59(d,J=8.3Hz,2H),5.91(s,2H,NH2)。13C NMR(101MHz,DMSO-d6)δ157.31(d,J=262.2Hz,2C),151.19,134.17(dd,J=21.5,4.8Hz,2C),133.48(2C),113.62(2C),109.81(t,J=16.7Hz),106.67(t,J=2.9Hz),105.47,71.86。HRMS(ESI)理论计算C13H9F2N2[MH+]:231.0728。实际测定:231.0730。理论分析计算C13H8F2N2:C,67.82;H,3.50;N,12.17。实际测定:C,67.64;H,3.69,N,12.10。
4-((3,5-二氟吡啶-4-基)乙炔基)-N-甲基苯胺(7c).收率54%;用1:5乙酸乙酯-己烷的制备层色谱法(Rf=0.26);mp 149-151℃。1H NMR(400MHz,DMSO-d6)δ8.60(s,2H),7.35(d,J=8.6Hz,2H),6.58(d,J=8.6Hz,2H),6.49(q,J=5.0Hz,1H),2.72(d,J=5.0Hz,3H)。13C NMR(101MHz,DMSO-d6)δ157.30(d,J=262.2Hz,2C),151.50,134.17(dd,J=21.6,4.9Hz,2C),133.41(2C),111.54(2C),109.80(t,J=16.6Hz),106.66(t,J=2.8Hz),105.34,72.10,29.16。HRMS(ESI)理论计算C14H11F2N2[MH+]:245.0885。实际测定:245.0885。理论分析计算C14H10F2N2:C,68.85;H,4.13;N,11.47。实际测定:C,68.64;H,4.40,N,11.27。
4-((3,5-二氟吡啶-4-基)乙炔基)-N,N-二甲基苯胺(7d).收率78%;用1:5乙酸乙酯-己烷的制备层色谱法(Rf=0.47);mp 139-140℃。1H NMR(400MHz,DMSO-d6)δ8.60(s,2H),7.43(d,J=8.5Hz,2H),6.74(d,J=8.6Hz,2H),2.99(s,6H)。13C NMR(101MHz,DMSO-d6)δ157.32(d,J=262.4Hz,2C),151.14,134.21(dd,J=21.6,4.8Hz,2C),133.21(2C),111.80(2C),109.67(t,J=16.7Hz),106.17(t,J=2.9Hz),105.72,72.48,39.59(2C)。HRMS(ESI)理论计算C15H13F2N2[MH+]:259.1041。实际测定:259.1041。理论分析计算C15H12F2N2:C,69.76;H,4.68;N,10.85。实际测定:C,69.50;H,4.78,N,10.78。
细胞增殖试验.LS174T细胞在补充有5%胎牛血清和1%青霉素/链霉素的RPMI培养基(Mediatech)中生长。对于细胞增殖试验,用DMSO或抑制剂处理在12孔板中生长的3x104个细胞/孔。4天后通过Vi-Cell Cell Viability Analyzer分析细胞数目和存活力。用GraphPad Prim 5计算IC50值。
蛋白质印迹.如前所述进行蛋白质印迹。使用以下抗体:抗c-myc(Epitomics,1472-1),抗-p21Wif1/Cip1(Cell Signaling,2947),抗-β-微管蛋白(DSHB,E7)。
在本发明中仅示出和描述了本发明的优选实施方式及其多功能性的实施例。应该理解的是,本发明能够用于各种其他组合和环境,并且能够在本文所表达的本发明构思的范围内进行改变或修改。因此,例如本领域技术人员将认识到或能够确认,使用不超过常规实验,本文所述的特定物质、程序和布置的许多等同方式。这样的等同方式被认为是在本发明的范围内,并且由以下权利要求覆盖。
Claims (5)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202211430818.8A CN115710215B (zh) | 2017-06-21 | 2018-06-21 | 用于治疗癌症的苯乙炔基取代苯和杂环及其应用 |
Applications Claiming Priority (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762523081P | 2017-06-21 | 2017-06-21 | |
US62/523,081 | 2017-06-21 | ||
US201862636463P | 2018-02-28 | 2018-02-28 | |
US62/636,463 | 2018-02-28 | ||
US15/976,643 US10449186B2 (en) | 2017-06-21 | 2018-05-10 | Phenylethynyl-substituted benzenes and heterocycles for the treatment of cancer |
US15/976,643 | 2018-05-10 | ||
CN202211430818.8A CN115710215B (zh) | 2017-06-21 | 2018-06-21 | 用于治疗癌症的苯乙炔基取代苯和杂环及其应用 |
CN201810643008.8A CN109096178B (zh) | 2017-06-21 | 2018-06-21 | 用于治疗癌症的苯乙炔基取代苯和杂环及其应用 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201810643008.8A Division CN109096178B (zh) | 2017-06-21 | 2018-06-21 | 用于治疗癌症的苯乙炔基取代苯和杂环及其应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN115710215A true CN115710215A (zh) | 2023-02-24 |
CN115710215B CN115710215B (zh) | 2024-06-04 |
Family
ID=64691717
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202211429525.8A Active CN115650904B (zh) | 2017-06-21 | 2018-06-21 | 用于治疗癌症的苯乙炔基取代苯和杂环及其应用 |
CN202211430818.8A Active CN115710215B (zh) | 2017-06-21 | 2018-06-21 | 用于治疗癌症的苯乙炔基取代苯和杂环及其应用 |
CN201810643008.8A Active CN109096178B (zh) | 2017-06-21 | 2018-06-21 | 用于治疗癌症的苯乙炔基取代苯和杂环及其应用 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202211429525.8A Active CN115650904B (zh) | 2017-06-21 | 2018-06-21 | 用于治疗癌症的苯乙炔基取代苯和杂环及其应用 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201810643008.8A Active CN109096178B (zh) | 2017-06-21 | 2018-06-21 | 用于治疗癌症的苯乙炔基取代苯和杂环及其应用 |
Country Status (2)
Country | Link |
---|---|
US (1) | US10449186B2 (zh) |
CN (3) | CN115650904B (zh) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104774156A (zh) * | 2014-03-26 | 2015-07-15 | 肯塔基大学研究基金会 | 卤代二芳基乙炔类似物、其药物组合物及其制备方法与应用 |
WO2016124160A1 (zh) * | 2015-02-06 | 2016-08-11 | 华东理工大学 | 作为egfr抑制剂的嘧啶并嘧啶二酮衍生物及其应用 |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW544448B (en) * | 1997-07-11 | 2003-08-01 | Novartis Ag | Pyridine derivatives |
WO2003024931A1 (en) * | 2001-09-14 | 2003-03-27 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
US6951875B2 (en) | 2001-10-29 | 2005-10-04 | Hoffmann-La Roche Inc. | Conjugated aromatic compounds with a pyridine substituent |
US7915424B2 (en) * | 2004-03-22 | 2011-03-29 | Eli Lilly And Company | Pyridyl derivatives and their use as mGlu5 antagonists |
US8334403B1 (en) * | 2005-12-22 | 2012-12-18 | Florida State University Research Foundation, Inc. | C-lysine conjugates as pH-controlled, light-activated reagents for double stranded DNA cleavage and associated methods |
WO2007087395A2 (en) * | 2006-01-25 | 2007-08-02 | Osi Pharmaceuticals, Inc. | UNSATURATED mTOR INHIBITORS |
WO2009055674A1 (en) * | 2007-10-26 | 2009-04-30 | Targegen Inc. | Pyrrolopyrimidine alkynyl compounds and methods of making and using same |
AU2009206775A1 (en) * | 2008-01-22 | 2009-07-30 | Merck Patent Gmbh | Protein kinase inhibitors and use thereof |
EP2411057B1 (en) * | 2009-03-23 | 2020-05-06 | Eli Lilly and Company | Imaging agents for detecting neurological disorders |
TW201116532A (en) * | 2009-08-05 | 2011-05-16 | Merz Pharma Gmbh & Co Kgaa | Metabotropic glutamate receptor modulators |
CN103524394A (zh) * | 2012-07-04 | 2014-01-22 | 华南师范大学 | 一种含氟氮杂环炔类液晶化合物合成方法与应用 |
JP2016507537A (ja) * | 2013-02-07 | 2016-03-10 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングMerck Patent Gesellschaft mit beschraenkter Haftung | 置換アセチレン誘導体およびmGluR4の正のアロステリックモジュレーターとしてのそれらの使用 |
US9233968B1 (en) * | 2014-10-27 | 2016-01-12 | Allergan, Inc. | Kinase inhibitors |
-
2018
- 2018-05-10 US US15/976,643 patent/US10449186B2/en active Active
- 2018-06-21 CN CN202211429525.8A patent/CN115650904B/zh active Active
- 2018-06-21 CN CN202211430818.8A patent/CN115710215B/zh active Active
- 2018-06-21 CN CN201810643008.8A patent/CN109096178B/zh active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104774156A (zh) * | 2014-03-26 | 2015-07-15 | 肯塔基大学研究基金会 | 卤代二芳基乙炔类似物、其药物组合物及其制备方法与应用 |
WO2016124160A1 (zh) * | 2015-02-06 | 2016-08-11 | 华东理工大学 | 作为egfr抑制剂的嘧啶并嘧啶二酮衍生物及其应用 |
Also Published As
Publication number | Publication date |
---|---|
CN109096178A (zh) | 2018-12-28 |
CN115710215B (zh) | 2024-06-04 |
CN115650904B (zh) | 2024-05-14 |
CN115650904A (zh) | 2023-01-31 |
US20180369222A1 (en) | 2018-12-27 |
US10449186B2 (en) | 2019-10-22 |
CN109096178B (zh) | 2022-12-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Hung et al. | Synthesis and cytotoxicity of thieno [2, 3-b] pyridine and furo [2, 3-b] pyridine derivatives | |
CA3030510C (en) | Azole dione compounds with anti-cancer activity | |
JP5956653B2 (ja) | 1−(5−tert−ブチル−2−フェニル−2H−ピラゾール−3−イル)−3−[2−フルオロ−4−(1−メチル−2−オキソ−2,3−ジヒドロ−1H−イミダゾ[4,5−B]ピリジン−7−イルオキシ)−フェニル]−尿素および関連化合物ならびに治療におけるそれらの使用 | |
CN102977014B (zh) | 新的喹啉类化合物及其用途 | |
CA2890981A1 (en) | Amide-substituted heterocyclic compounds useful as modulators of il-12, il-23 and/or ifn.alpha. responses | |
CA2926328A1 (en) | Substituted quinazolinyl and quinolinyl derivatives and pharmaceutical compositions thereof useful as inhibitors of kras g12c | |
CZ20031424A3 (cs) | Deriváty naftalenu, způsob jejich přípravy a jejich použití ve farmaceutických prostředcích | |
CN111051300B (zh) | 作为组蛋白脱乙酰基酶1和/或2(hdac1-2)的选择性抑制剂的新杂芳基酰胺衍生物 | |
WO2013013614A1 (zh) | 4-(3-杂芳基芳基氨基)喹唑啉和1-(3-杂芳基芳基氨基)异喹啉作为Hedgehog通路抑制剂及其应用 | |
Li et al. | Design, synthesis, biological evaluation and structure-activity relationship of sophoridine derivatives bearing pyrrole or indole scaffold as potential antitumor agents | |
AU2020271268A1 (en) | Inhibitors of notch signalling pathway and use thereof in treatment of cancers | |
Hu et al. | Synthesis and biological evaluation of 1-cyano-2-amino-benzimidazole derivatives as a novel class of antitumor agents | |
EP2970128B1 (en) | Base addition salts of nitroxoline and uses thereof | |
CN109081813B (zh) | 一类苯并杂环类化合物及其治疗癌症的用途 | |
EP3813784B1 (en) | Prc1 inhibitors and prc1 inhibitors for use in methods of treatment therewith | |
CN109096178B (zh) | 用于治疗癌症的苯乙炔基取代苯和杂环及其应用 | |
WO2020077944A1 (zh) | 嘌呤系列衍生物及其制备方法和用途 | |
EP4230204A1 (en) | Thiobenzimidazole derivative or pharmaceutically acceptable salt thereof and use thereof | |
CN107635991B (zh) | 作为tdp2的抑制剂的呋喃并喹啉二酮 | |
A Mahajan et al. | Synthesis of novel amides based on acridone scaffold with interesting antineoplastic activity | |
US9895324B2 (en) | Halogenated diarylacetylenes and methods of treating cancer | |
WO1996010015A1 (en) | Cryptolepine analogs with hypoglycemic activity | |
CN112939966B (zh) | 嘧啶衍生物、其制备及应用 | |
US20230121233A1 (en) | Heteroaryl compounds as inhibitors of programmed necrosis pathway, composition and method using the same | |
KR101589632B1 (ko) | 항암활성을 가지는 6-벤질옥시퀴나졸린-7-일유레아 유도체 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |